

PROTOCOL

The Restoring Insulin Secretion (RISE) Study

RISE Pediatric Medication Study



RISE Study Group

Date: May 1, 2016

Version 1.3

Distributed by
RISE Study Data Coordinating Center
Biostatistics Center
George Washington University
6110 Executive Boulevard
Rockville, Maryland 20852

CONFIDENTIAL

TABLE OF CONTENTS

1	Executive Summary.....	7
1.1	Specific Aims and Objectives	8
1.2	Overall Design and Study Interventions	9
2	Background and Significance	10
2.1	Prediabetes and Type 2 Diabetes: Epidemiology, Natural History and Pathogenesis.....	10
2.2	Obstructive Sleep Apnea (OSA) and Diabetes Risk	12
2.3	Results of Type 2 Diabetes Prevention Studies	12
2.4	Long Term Intervention Studies in Patients with Early Type 2 Diabetes	13
2.5	Metformin	16
2.6	Insulin Glargine	17
2.7	Approaches to Measuring β -cell Function, α -cell Function, Insulin Sensitivity and Glucose Tolerance	17
2.7.1	Intravenous Tests of β - and α -cell Function and Insulin Sensitivity.....	18
2.7.2	Oral Tests of β - and α -cell Function and Insulin Sensitivity	19
2.8	Biomarkers of β -cell Function, α -cell Function, Insulin Sensitivity and Glucose Tolerance	20
2.8.1	Putative Diabetes Biomarkers.....	20
3	STUDY DESIGN.....	21
3.1	Overview and Rationale	21
3.2	Primary Outcomes	22
3.3	Secondary Outcomes	23
3.3.1	β -cell Function and Glucose Tolerance	23
3.3.2	α -cell Function.....	24
3.3.3	Insulin Sensitivity	25

3.3.4 Blood and Urine Biomarkers 25

3.3.5 Physical and Body Composition Measures 25

3.4 Treatments..... 25

3.4.1 Three-week Placebo Run-in Phase..... 25

3.4.2 Twelve-month Active Treatment Phase..... 26

3.4.3 Metformin 26

3.4.4 Insulin Glargine Followed by Metformin 26

3.4.5 Medication Wash-out and Post-treatment Follow Up 27

3.4.6 Rescue 27

3.5 Inclusion Criteria 27

3.6 Exclusion criteria 28

3.7 Randomization 29

3.8 Masking 29

4 RECRUITMENT..... 30

4.1 Recruitment 30

4.2 Description/Justification of the Target Study Population..... 30

4.3 Informed Consent 31

4.4 Staged Screening and Randomization 32

5 PATIENT MANAGEMENT..... 34

5.1 Description of RISE Research Facility Treatment(s) 34

5.2 Drug Distribution..... 34

5.3 Adherence Measures 34

5.3.1 Placebo Run-in 35

5.3.2 Insulin..... 35

5.4 Retention 35

6	DATA COLLECTION	36
6.1	Main Study Procedures.....	36
6.1.1	Fasting Blood and Urine Samples.....	36
6.1.2	Oral Glucose Tolerance Test (OGTT).....	36
6.1.3	Hyperglycemic Clamp.....	37
6.2	Eligibility Screening Measurements.....	37
6.3	Baseline and Post-Randomization Measures.....	39
6.3.1	Physical Measures.....	41
6.3.2	Sleep Assessments	42
6.3.3	Safety Measures.....	42
6.3.4	Participant Protocol Adherence.....	42
6.4	Visit Windows	42
7	SAFETY / HUMAN SUBJECTS PROTECTION	43
7.1	Data and Safety Monitoring Board (DSMB).....	43
7.2	Data and Safety Monitoring Plan.....	43
7.2.1	Informed Consent	43
7.2.2	Safety Review Plan and Monitoring.....	44
7.2.3	Confidentiality.....	44
7.3	Expected Side Effects	45
7.4	Risk Management	45
7.5	Potential Benefits.....	49
7.6	HIPAA – Protection of Patient Information.....	49
8	ADVERSE EVENT REPORTING	50
8.1	Definition of Serious Adverse Events.....	50
8.2	Non-serious Adverse Events	50

8.3	Reporting Adverse Events.....	50
8.4	Tracking Adverse Events.....	51
8.5	Emergency Unmasking.....	51
9	STATISTICAL CONSIDERATIONS.....	51
9.1	Primary Outcome and Analyses.....	52
9.2	Secondary Outcomes and Analyses.....	52
9.2.1	Measures of β - and α -cell Function and Glucose Tolerance.....	52
9.3	Sample Size/Power Calculations.....	53
9.4	Interim Analysis Plans.....	53
9.5	Stopping Rules.....	53
9.6	Handling of Missing Data.....	54
10	DATA PROCESSING AND MANAGEMENT.....	54
10.1	Data Management System.....	54
10.2	Data Transfer.....	54
10.3	Quality Control.....	54
10.4	Back-up, Data Security and Confidentiality.....	55
10.5	Tracking Study Progress.....	55
10.6	Archiving and Study Close-out.....	55
11	STUDY ADMINISTRATION.....	56
11.1	Organization.....	56
11.2	Central Laboratories and Reading Centers.....	57
11.3	Training and Certification.....	57
11.4	Site Visits.....	58
11.5	Study Website.....	58
11.6	Conflict of Interest Policy.....	59

11.7 Publications and Presentations Policy 59

11.8 Ancillary Studies Policy 60

11.9 Protocol Amendments 60

11.10 Repository for Storage and Distribution of RISE Data and Samples 61

12 STUDY TIMELINE 61

13 LITERATURE CITED 61

1 Executive Summary

Type 2 diabetes in youth is associated with the onset of multiple diabetes-related complications in the teenage and early adult years, such as microalbuminuria, retinopathy, hypertension, cardiac hypertrophy, dyslipidemia and nonalcoholic fatty liver disease. In adults with type 2 diabetes, these complications are usually not seen until well into the course of the disease; therefore, their onset in adolescence is concerning and predicts very early morbidity and mortality for youth with type 2 diabetes. In addition, the recent Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study found that approximately 50% of youth failed treatment with metformin within 2 years, a much more rapid failure rate than in adults, and while rosiglitazone was more effective, it is no longer used in youth due to safety concerns [1]. Therefore, since metformin was not effective in early diabetes in TODAY, intervening earlier at the stage of prediabetes may be of more benefit. In addition, new interventions that can interrupt this disease process at an early stage of diabetes are a critical need in youth.

A core defect in the pathogenesis of type 2 diabetes involves the β -cell, which has been shown to be dysfunctional in youth with prediabetes, a high risk state that is antecedent to type 2 diabetes, as well as in established type 2 diabetes [2]. In addition to β -cell failure, insulin resistance and α -cell dysfunction are prominent features leading to type 2 diabetes onset [2-4]. Defects in both insulin sensitivity and beta cell dysfunction are present long before the diagnosis of diabetes in obese youth, arguing for early intervention [5-13].

The possibility that improvements in β -cell function in type 2 diabetes can be achieved and maintained for a period of time after withdrawal of a dietary or pharmacological intervention has been suggested by results from small studies in adults with varying degrees of hyperglycemia treated aggressively with insulin, oral hypoglycemic drugs and diet [14-16]. These studies demonstrate that, at least for some patients, β -cell function can be improved. However, it is unclear whether any beneficial effect on β -cell function can be maintained and the natural history of progressive loss of β -cell function altered, especially among youth, in whom the progression of β -cell failure appears more rapid than adults [1]. Further, while these studies focused on the β -cell, they did not consider the possibility that producing a sustained improvement in α -cell function may also be important in slowing progression of glucose intolerance.

Numerous medications, acting by different mechanisms, are available to treat type 2 diabetes in adults. All lower blood glucose. Metformin, which has been approved for use in the pediatric population, is thought to reduce hepatic glucose production and improve insulin resistance; it has been shown to prevent progression of prediabetes to diabetes in adults [17]. Insulin lowers glucose while providing β -cell “rest”, and reducing the effects of gluco/lipotoxicity. Insulin

sensitizers may also improve β -cell function indirectly by reducing β -cell stress [18, 19]. Sulfonylureas initially improve β -cell function but may accelerate secondary failure [18, 19]. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and other incretin-based therapies improve islet function [20, 21], but their ability to prevent diabetes and/or slow its progression is unknown.

The RISE (Restoring Insulin Secretion) Study consortium is comprised of seven clinical centers. Investigators at these centers will conduct three different protocols to assess the feasibility of different interventions in adults and children to preserve or improve β -cell function in individuals with prediabetes or recent-onset type 2 diabetes. Four centers who are very experienced in studies of insulin insensitivity and secretion in youth [5-13, 22-24] (the topic of research supported by this protocol) will participate in a pediatric study performing a randomized trial comparing early intensive insulin treatment with insulin glargine (Lantus®) followed by metformin, with metformin treatment alone. These centers are located at the University of Colorado, University of Pittsburgh, Yale University and Indiana University. In addition, three adult centers will together perform a randomized, partially blinded, placebo-controlled trial comparing three treatment regimens versus placebo. The three treatment regimens are: (1) metformin alone, (2) early intensive insulin treatment with insulin glargine (Lantus®) followed by metformin, or (3) liraglutide plus metformin. These adult centers are located at the VA Puget Sound Health Care System / University of Washington, University of Chicago and Indiana University. One additional adult center at the University of Southern California will perform a randomized trial comparing the effects of gastric band obesity surgery to metformin on β -cell function. The three protocols will use many of the same inclusion and exclusion criteria, study procedures, timeline and outcome measures to allow for comparisons among groups and interventions. The overall goal of each active intervention is to reduce glucose levels to near normal during a 12-month treatment period and determine whether this slows deterioration or induces recovery of β - and α -cell function and produces a prolonged remission, i.e. sustained improvement in islet function that is associated with improved glycemia after the intervention has been discontinued. Achieving sustainable remissions will be a step in developing new treatments for prediabetes and early type 2 diabetes that can delay development or slow progression of the disease.

This protocol describes the study that will be performed at four centers in a pediatric population with type 2 diabetes or pre-diabetes.

1.1 Specific Aims and Objectives

The primary objective of the RISE Pediatric Medication Study is to compare, in a preliminary proof-of-principle trial, the efficacy of two treatment strategies on measures of β -cell function

after 3-months of post-treatment washout that will follow 12 months of active treatment. Participants will have prediabetes or recent-onset type 2 diabetes, defined by elevations in 2-hour post-challenge glucose levels along with elevations in hemoglobin A1c and/or fasting glucose concentrations. The hypothesis is that, in participants with prediabetes or recent-onset type 2 diabetes, initial aggressive glucose lowering with insulin glargine (Lantus®) for three months followed by metformin will lead to preservation or recovery of islet function that will be sustained off treatment when compared to metformin alone. To address this hypothesis, we have identified the following primary and secondary specific aims.

The primary specific aim is to determine whether:

- Improvements in β -cell function following 12 months of active treatment with initial insulin glargine (Lantus®) (three months) followed by metformin (9 months) will be maintained for at least 3 months after the withdrawal of therapy, more effectively than treatment with metformin alone.

The secondary specific aims are to determine whether:

- Treatment with initial insulin glargine (Lantus®) followed by metformin for 12 months improves β -cell function compared to metformin alone at 12 months,
- Improvements in β -cell function are maintained for 9 months after withdrawal of initial insulin glargine (Lantus®) followed by metformin, compared to metformin alone.
- Treatment with initial insulin glargine (Lantus®) followed by metformin for 12 months improves α -cell function compared to metformin alone, and whether this improvement is maintained after withdrawal of therapy,
- Measures of β - and α -cell function from an oral glucose tolerance test (OGTT) and fasting samples made on and off therapy are sufficiently well correlated with more robust and technically demanding assessments, validating use of the simpler measures in large clinical trials, and
- Biomarkers obtained at baseline can predict parameters of β - and α -cell function, insulin sensitivity and glucose tolerance and the response to an intervention.

1.2 Overall Design and Study Interventions

The RISE Pediatric Medication Study is a preliminary proof-of-principle, two-arm open-label study in which volunteers with prediabetes or recent onset type 2 diabetes (HbA1c levels $\leq 8.0\%$ if treatment naïve, $\leq 7.5\%$ if on metformin for < 3 months and $\leq 7.0\%$ if on metformin for

3-6 months, fasting glucose ≥ 90 mg/dl and 2-hour glucose ≥ 140 mg/dl post 75 gram oral glucose challenge) are randomized to: (1) metformin alone, or (2) initial insulin glargine (Lantus®) for three months followed by metformin. The study will recruit participants over a three-year period and follow them for a total of 21 months from randomization. The primary outcome measure is β -cell function as determined in two ways, as defined below. The anticipated duration of the RISE Study is five years, including pre-trial planning and post-trial analysis and reporting.

β -cell function, α -cell function, insulin sensitivity and glucose tolerance will be assessed using intravenous and oral tests. Both intravenous and oral tests will be obtained at baseline, after 12 months of therapy and 3 months after treatment has been stopped. In addition, oral tests will be done at 6 months on therapy, and 9 months off treatment. From these intravenous and oral tests as well as fasting samples, we will assess the sustainability of induced improvements and determine how well simpler measures of β -cell function, α -cell function and insulin sensitivity correlate with more sophisticated measures. Finally, a series of biomarkers will be measured to determine whether they predict β - and α -cell function, insulin sensitivity and glucose tolerance, as well as the response to therapy. Since preliminary data suggest that not all patients with diabetes respond, predictive biomarkers will be valuable for determining those individuals with the best chance of responding to intensified early treatments.

This study will provide critical information about the ability of early aggressive treatment approaches to lead to sustained recovery of islet function in youth, and whether such approaches should be studied in larger clinical trials. Further, this study will provide valuable information regarding the potential use of simpler measures of glucose metabolism in youth, as well as biomarkers that can be used in future clinical studies and, ultimately, in patient care.

2 Background and Significance

2.1 Prediabetes and Type 2 Diabetes: Epidemiology, Natural History and Pathogenesis

The increasing prevalence of obesity in youth and adults has been associated with a relentless rise in the prevalence of type 2 diabetes and prediabetes (impaired glucose tolerance [IGT] and/or impaired fasting glucose [IFG]). In the United States, there are currently nearly 26 million people, or 11.3% of the population aged 20 years or older, with diabetes; the incidence is estimated at 1.9 million new cases annually [25]. Over 90 percent of these cases are type 2 diabetes. In addition, approximately 79 million, or 35% of the same age group, have prediabetes [25]. In the United States during the period 2002-2005, 3,600 youth were newly

diagnosed with type 2 diabetes annually. The estimated rate of new cases of type 2 diabetes in youth aged <10 years was 0.4 per 100,000 per years, with the rate increasing in those 10-19 years of age to 8.5 per 100,000 per year [26]. Of note, the rate was greater in children and adolescents from minority groups [26]. Amongst adolescents, the 2005-2006 National Health and Nutrition Examination Survey (NHANES) estimated the prevalence of prediabetes to be 16.1% [27].

While both diabetes and prediabetes are defined by levels of fasting and/or 2-hour plasma glucose [28] or HbA1c [29], the disorders are a continuum. Individuals with prediabetes are at very high risk of developing diabetes [17, 30-32], while those with established diabetes exhibit a progressive loss of glucose control [33]. Since data indicate that beta cell function declines with duration of sustained hyperglycemia, early interventions may be essential to achieve the best results.

The pathogenesis of diabetes and prediabetes involves two major defects: insulin resistance and β -cell dysfunction [2, 34]. Although improvements in insulin sensitivity can slow progression of both disorders, ultimately, progressive β -cell dysfunction is critical for both the development [35] and progression [19] of type 2 diabetes. The β -cell abnormality has been demonstrated to comprise abnormalities in both insulin release in response to glucose and non-glucose secretagogues, as well as a defect in the ability of the β cell to efficiently process proinsulin to insulin [2, 36]. In obese youth, defects in both insulin sensitivity and beta cell dysfunction are present long before the diagnosis of diabetes [5]. The decline in β -cell function may also be more rapid than in adults [37, 38], but also potentially more reversible due to the recent onset, and therefore may involve unique pathophysiology. Therefore, studies in youth separate from adults are required.

The progressive loss of the ability to release insulin determines the deterioration of glycemia [34, 39, 40], and thereby sets up a vicious cycle in which the metabolic derangements (“glucolipotoxicity”) associated with type 2 diabetes beget further β -cell dysfunction [41]. In addition to β -cell dysfunction, β -cell volume (“mass”) is reduced in type 2 diabetes and possibly in those with prediabetes [42-44]. This loss of β -cells may result from or be accelerated by glucolipotoxicity [41] and other abnormalities such as amyloid deposition that impact the islet [45].

Aside from the β -cell lesion, a functional abnormality of the islet α -cell also contributes to hyperglycemia in type 2 diabetes [3, 46, 47]. While fasting glucagon levels may or may not be elevated [3], normal suppression of glucagon following oral nutrient ingestion does not occur, but rather a paradoxical increase in glucagon levels can occur [3, 46, 47]. Further, during hyperglycemic clamps, glucagon release is greater in patients with type 2 diabetes than in

healthy subjects [48]. Finally, α -cell dysfunction is present in subjects with IGT [49, 50] and first-degree relatives of individuals with type 2 diabetes [51], both groups at increased risk of developing type 2 diabetes. Thus, α -cell dysregulation appears to also be an early feature of the islet lesion in patients with type 2 diabetes and those at high risk.

2.2 Obstructive Sleep Apnea (OSA) and Diabetes Risk

The alarming increase in overweight and obesity plays a pivotal role in the rise in diabetes prevalence. The obesity epidemic has in turn resulted in an increased prevalence of OSA, a treatable sleep disorder involving shallow and fragmented sleep as well as intermittent hypoxia. In adults OSA is a well-documented risk factor for glucose intolerance, insulin resistance and diabetes, independently of body mass index [52, 53], while in youth it has been shown to be associated with markers of diabetes risk including visceral adiposity and insulin resistance [54, 55]. Further, studies have shown that OSA is a frequent co-morbidity of diabetes in adults with a prevalence averaging 68% [56-58]. To date, however, clinical trials in youth or adults with prediabetes or diabetes have not taken the presence and severity of this co-morbidity into account. Thus, we will make assessments of sleep by questionnaire and examine whether disturbed sleep impacts the progression of β - and α -cell function over time and the impact of the glucose-lowering intervention.

2.3 Results of Type 2 Diabetes Prevention Studies

A number of studies have established the ability to slow the progression from prediabetes to diabetes in adults. Overall, the greatest success has been achieved with the three thiazolidinediones (TZDs) which in TRIPOD (Troglitazone In the Prevention of Diabetes), DPP (Diabetes Prevention Program), DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) and ACT NOW (Actos Now for Prevention of Diabetes) reduced the short-to-intermediate risk of deterioration in glycemic control by 55-72% [31, 59-61], rates similar to or greater than the 58% risk reduction observed with lifestyle interventions in the DPP and FDS (Finnish Diabetes Prevention Study) [17, 30, 59]. The DPP also demonstrated that metformin reduced the risk of progression to diabetes by 31% over three years in adults [59]. Other large studies examining the effects of medications showed that acarbose in STOP-NIDDM decreased the risk by 25% [62], but the β -cell secretagogue nateglinide did not reduce the risk of progression to diabetes in NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) [63]. The ORIGIN (Outcome Reduction With Initial Glargine Intervention) study showed that insulin glargine reduced the risk of developing diabetes by 28% while participants were on therapy, and importantly, by 20% 100 days after withdrawal of therapy [64]. Therefore long-term glargine may have durable effect on reducing diabetes risk in adults. Shorter duration of insulin therapy, and insulin's impact on actual beta or alpha cell

function have not been tested yet, in adults or youth.

Medication combinations have had variable effects, with low dose rosiglitazone plus metformin in CANOE (Canadian Normoglycemia Outcomes Evaluation) producing a comparable effect to that reported in other studies where larger doses of a TZD were used [65].

Follow up after discontinuation of the intervention, with the aim of assessing the durability of the intervention effects has only been undertaken in a few instances. In the FDS, withdrawal of the lifestyle intervention was associated with continued risk reduction three years later [66]. In DREAM On, after withdrawal of rosiglitazone, the annual incidence of diabetes was similar in those who were or were not randomized to receive the medication, while the cumulative incidence in those previously exposed to active medication remained lower; this observation suggests a delay but not a reversal of the underlying disease process [59, 67, 68]. To date there has not been a systematic evaluation to determine whether interventions can slow the progression to diabetes by changing the underlying pathophysiology, particularly that of β -cell function.

While studies in the pediatric literature exist regarding risk factors for type 2 diabetes (obesity, insulin resistance, inactivity, etc.), there are no published type 2 diabetes prevention studies targeting youth or studies in youth with early type 2 diabetes. There is a study underway, but not yet completed, examining dietary interventions in adolescents with insulin resistance and/or prediabetes [69].

2.4 Long Term Intervention Studies in Patients with Early Type 2 Diabetes

Registration studies have examined the glucose-lowering effects of new medications for treating type 2 diabetes in adults. These studies frequently have been relatively short in duration (6-12 months) and follow up has typically been in the form of an open label extension lacking an active comparator. Importantly, with the exception of the UKPDS (United Kingdom Prospective Diabetes Study) and ADOPT (A Diabetes Outcome Progression Trial), long-term effects on β -cell function have not been determined.

In the UKPDS, patients with recently diagnosed diabetes received “intensive” treatment with a sulfonylurea, insulin [33] or metformin [70] for an average of 10 years. After the first year, fasting glucose and HbA1c increased at similar rates in both the “intensive” and “conventional” treatment groups, firmly establishing the progressive nature of the disease [33, 70]. This deterioration in both groups was shown to be due to relentless β -cell failure [71]. Why insulin did not prevent progression of β -cell dysfunction is unclear, but, if our current hypothesis is

correct, may be because HbA1c was not reduced to normal or near normal levels, reaching a nadir of about 6.4% at the end of the first year of treatment.

The findings in the UKPDS contrast with those in other studies in which short-term treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) improved β -cell function after fasting glucose was normalized [14-16]. The largest of these studies was performed in 382 Chinese adults with fasting plasma glucose levels of >126 mg/dl who were randomly assigned to therapy with insulin (MDI or CSII) or oral glucose-lowering medications in order to rapidly correct the elevated glucose and maintain it in the normal range for two weeks. Patients were subsequently prescribed diet and exercise alone and followed for a year. More subjects in the two insulin groups achieved the target glycemic level and did so in less time than those using oral agents. Remission rates after one year were significantly higher in the insulin groups (51.1% in CSII and 44.9% in MDI) than in the group taking oral glucose lowering therapy (26.7%; $p=0.0012$). β -cell function in the remission group, determined by HOMA B (homeostatic model assessment β -cell index) and the acute insulin response to glucose, improved significantly after the intensive interventions, and was better sustained in the insulin groups after one year.

ADOPT compared rosiglitazone, metformin and glyburide in patients with recently diagnosed (<3 years) diabetes [18]. Over a median of four years, rosiglitazone reduced the progression of hyperglycemia more effectively than did glyburide, with metformin being intermediate in its effect. The glyburide-induced increase in secretory output was associated with a more rapid loss of β -cell function than “resting” the β -cell by decreasing secretory demand with rosiglitazone [18, 19]. Importantly, patients who failed monotherapy had higher fasting glucose and HbA1c levels and lower β -cell function at baseline, and demonstrated the most marked decline in β -cell function irrespective of treatment assignment [19]. The use of rosiglitazone has since been severely restricted by the U.S. Food and Drug Administration (FDA) because of concerns about associated cardiovascular events. The other TZD, pioglitazone, remains available but has been associated with bladder cancer [72, 73]. In addition, this class of drugs has been associated with weight gain, edema and fractures [18], side effects that further limit the attractiveness of these drugs in individuals early in the course of disease.

The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study examined whether metformin plus rosiglitazone, or metformin plus a lifestyle intervention were superior to metformin alone in maintaining glycemic control when initiated early in the course of youth-onset type 2 diabetes [1]. In participants aged 10 to 17 years, the study demonstrated that monotherapy with metformin was ineffective in maintaining glycemic control in half of the adolescents with type 2 diabetes, a failure rate much higher than expected from adult studies

with the medication. Addition of rosiglitazone, but not intensive lifestyle, was superior to metformin alone. Insulin sensitivity improved significantly at 6 months with metformin plus rosiglitazone, but not with the other two interventions. There was also a significant improvement in β -cell function with metformin plus rosiglitazone, while with metformin alone and metformin plus lifestyle β -cell function deteriorated. Importantly, a higher HbA1c at baseline was predictive of β -cell decline. Given the safety concerns regarding rosiglitazone, this medication is no longer suitable for use in youth. Alternative approaches to preserving beta cell function are needed.

Incretin-based therapies hold new promise for promoting recovery and preservation of islet function. They not only increase insulin secretion and decrease glucagon release, but also preserve the morphology of cultured human islets [74] and increase β -cell mass following partial pancreatectomy in rodents [75]. In humans, long-term intervention studies with these agents are limited. The only study examining the potential for durability compared the effect of three years of treatment with the GLP-1RA exenatide to insulin glargine in a small number of patients who were also taking metformin. HbA1c (7.4-7.6% at baseline) was reduced similarly in both groups to 6.7-6.8% after one year of therapy in 69 participants, with the exenatide group demonstrating improved β -cell function while the insulin glargine group showed no change. Following one month of washout, β -cell function was similar to pretreatment values in both groups [76]. Thereafter, therapy was restarted in a subgroup, and was continued to three years in 36 participants, at which time one month of medication withdrawal was associated with better β -cell function in the exenatide group, in keeping with a benefit beyond the period of exposure [77]. The magnitude of improvement was small, however, and it is unclear whether the need for prolonged therapy to demonstrate a benefit was because subjects had long standing diabetes with poor β -cell function at baseline and/or the attained glucose level on therapy was not close enough to normal to achieve optimal effects during the initial treatment period. Incretin-based therapies such as liraglutide are associated with nausea, an increased risk of pancreatitis, and possibly an increased risk of thyroid cancer. Therefore, due to this risk profile and the lack of safety data in youth, the incretin family is not currently considered ideal for youth.

It may be that the greatest potential to induce prolonged remission will be with aggressive glucose lowering and in those with earlier disease and milder defects, possibly by reducing β -cell burden to produce and release insulin. This is supported by the observations that (a) in ADOPT those who failed monotherapy and those who failed oral therapy in TODAY had higher glucose levels and worse β -cell function at baseline, (b) the greatest success in slowing progression in those with prediabetes and early diabetes occurred with TZDs, which reduce β -cell secretory demand, and (c) the beneficial effect of exenatide was observed after prolonged

therapy in individuals with well-established diabetes in whom glucose levels were not near normal at baseline or during therapy. In addition, the defects in both insulin sensitivity and beta cell dysfunction leading to diabetes are present long before the diagnosis of the disease in obese youth. While in youth type 2 diabetes beta cell function relative to insulin sensitivity, β I, is 80% impaired, in obese youth with IFG and/or IGT it is ~ 45% impaired compared with equally obese youth with normal glucose tolerance [78]. Indeed, even prior to the development of impaired glucose tolerance, reductions in insulin sensitivity and early phase insulin secretion are present and are indistinguishable from those seen in the presence of established IGT [5].

Thus, we propose to study subjects with prediabetes or early type 2 diabetes who at baseline will have better β -cell function than those with a longer duration of diabetes. We will use therapeutic approaches acceptable for youth that aim to lower glucose to levels that are close to normal using metformin and insulin, that will decrease secretory demand on the β -cell.

2.5 Metformin

Metformin is a glucose lowering medication of the biguanide class that has been used in the management of type 2 diabetes for over 50 years. It reduces the excess hepatic glucose production that characterizes type 2 diabetes without increasing insulin secretion. In fact, in the DPP it was documented that the improvement in insulin sensitivity associated with metformin treatment resulted in a decrease in secretory demand and, thus, insulin release by the β -cell [35]. In addition to its glucose lowering action, an added potential benefit of metformin is a modest weight loss, and some protection from weight gain with other diabetes treatments including insulin [79, 80]. Metformin is not currently approved for use in the prevention of type 2 diabetes. However, the DPP demonstrated that metformin is effective in persons with impaired glucose tolerance, reducing the development of diabetes by 31% [17].

The most common side effects associated with metformin are gastrointestinal. As many as 30% of persons report diarrhea, nausea, metallic taste, abdominal bloating, flatulence or anorexia. These symptoms are generally transient, resolve spontaneously and can be avoided by gradual escalation of dosage. About 4% of participants were unable to continue metformin in U.S. clinical trials. Metformin is not associated with hypoglycemia unless used in conjunction with other glucose-lowering medications (sulfonylurea or insulin). Metformin has been found to rarely cause lactic acidosis (about 0.03 cases per 1,000 person years), and then only when used in persons with renal or hepatic insufficiency or during episodes of hypoxia or circulatory failure [79]. In youth, metformin has been well tolerated both in the treatment of type 2 diabetes and for weight loss [1, 81].

2.6 Insulin Glargine

Insulin glargine is a recombinant human insulin analogue that in most subjects is administered once daily, as it forms subcutaneous microprecipitates from which small amounts of this analogue are released, resulting in a relatively constant profile over 24 hours. It has been used since 2000 to treat patients with type 2 diabetes, is FDA-approved for use in adults with type 2 diabetes and youth with type 1 diabetes, and has recently been reported to reduce the risk of developing type 2 diabetes in individuals with prediabetes by 28% [64]. Insulin glargine administered at night lowers plasma glucose by decreasing hepatic glucose production [82] and can be titrated in individuals with prediabetes and established diabetes to achieve fasting glucose concentrations of <95 mg/dl without a marked increase in recurrent or severe hypoglycemia [64]. Glargine activity does not peak, unlike NPH insulin, and thus there is much less risk of hypoglycemia, especially overnight. In addition, due to its lack of a peak, subjects can safely skip meals or fast with glargine.

The most common side effects observed with insulin glargine are hypoglycemia and weight gain. This insulin has been reported in some non-randomized, epidemiological studies to be associated with an increased risk of cancer [83]. However, type 2 diabetes itself is associated with increased cancer risks, which is a likely confounder. In addition, ORIGIN, a randomized trial in which over 6,000 participants received insulin glargine for a median of 6.2 years, had minimal hypoglycemia and weight gain and did not observe an association between insulin glargine and cancer, nor with increased cardiovascular disease [64].

2.7 Approaches to Measuring β -cell Function, α -cell Function, Insulin Sensitivity and Glucose Tolerance

Glucose homeostasis is physiologically modulated under fasting and prandial conditions by a number of regulatory factors, most prominently insulin and glucagon. Measurements made under fasting conditions are frequently proportional to direct measures of the dynamic responses, but the most rigorous measurement of β -cell function (insulin and/or C-peptide responses to physiologic stimuli) comes from evaluation of dynamic tests. Dynamic testing can be accomplished with oral intake of glucose or mixed meals, or with intravenous infusion of glucose or other β -cell stimulators. In RISE studies, the hyperglycemic clamp technique will be used to examine insulin sensitivity and β -cell function, and the OGTT will be used as a complementary measure that more closely reflects the integrated physiologic response to ingested stimuli, including incretins.

2.7.1 Intravenous Tests of β - and α -cell Function and Insulin Sensitivity

Glucose tolerance is dependent on β -cell function and insulin sensitivity, and both of these can be quantified using the hyperglycemic clamp [84]. The role of α -cell function in determining glucose tolerance is less well defined.

The acute insulin (C-peptide) response to intravenous glucose (AIRg or first phase insulin response) occurs within the first ten minutes following bolus glucose administration and is a sensitive marker of β -cell function that decreases as the fasting glucose level rises. A potential “drawback” of this measure is that the first phase response drops sharply as the fasting glucose level approaches 115 mg/dl [85]. Above that level, the first-phase response is markedly diminished and frequently absent in adults, although less is known about it in youth. Although this early response may respond to treatment interventions aimed at restoring or preserving β -cell function in some patients, this defect, in the absence of medication, appears particularly resistant to reversal. The response is possibly related to the type of intervention used to bring about improvement in β -cell function. These difficulties with measuring early responses at baseline limit our ability to depend on this measure of β -cell function as a primary outcome in RISE.

The second phase insulin response to intravenous glucose begins at the time of glucose administration and continues for as long as the glucose level remains elevated. It is frequently quantified as part of a hyperglycemic clamp. Unlike the acute insulin response to glucose, the second phase response persists and is measurable even when the fasting glucose concentration exceeds 115 mg/dl in adults [86], but additional data is required in adolescents. Moreover, it is proportional to overall β -cell secretory capacity and can be measurably improved with treatment interventions targeting β -cell function [87]. Over time, once diabetes has developed, the overall insulin response to increased glucose levels becomes progressively blunted.

In addition to changes in glucose levels, β -cells also respond to non-glucose secretagogues, such as peptides and amino acids, and these responses can persist even after severe blunting of the glucose-induced response. The prevailing glucose level modulates the β -cell secretory response to non-glucose secretagogues. By performing hyperglycemic clamps with the addition of a bolus intravenous arginine injection, it is possible to quantify the maximum insulin response (AIRmax), which provides an estimate of the maximum β -cell secretory capacity under preexisting metabolic conditions at a given point in time. In the absence of techniques that provide a direct measure of β -cell mass in living humans, this secretory capacity is currently taken as an indirect measure of β -cell mass. AIRmax is decreased in patients with type 2 diabetes [48] and in those at risk of developing the disorder [88]. Again, unlike the first phase response, AIRmax responses are present and readily quantified in individuals with higher fasting

glucose levels (>115 mg/dl). However, little is known about this component of β -cell secretory capacity in youth, arguing for the need for assessment of this measure in youth in the proposed studies. Effects of treatment interventions on AIRmax have not been extensively evaluated but are beginning to be studied [77].

β -cell responses also are modulated by the prevailing insulin sensitivity. Therefore, expressing β -cell function relative to insulin sensitivity provides a better estimate of how well the β -cell is performing [89]. This approach of accounting for the effect of insulin sensitivity has been used extensively with AIRg derived from frequently sampled IV glucose tolerance tests, where the intravenous glucose tolerance test (IVGTT)-derived measure of insulin sensitivity (S_I) is used to produce the 'disposition index' ($S_I \times \text{AIRg}$) [89]. This approach can also be applied to adjust other measures of β -cell function, providing that the underlying assumption of a hyperbolic relationship between the insulin sensitivity variable and the β -cell function variable is true. Likewise, AIRmax can be adjusted for insulin sensitivity (e.g. $S_I \times \text{AIRmax}$; [89]). Insulin sensitivity-adjusted β -cell function measures derived from second phase responses and AIRmax responses measured with hyperglycemic clamp methods have been selected as the primary outcome measurements for RISE.

The reciprocal of glucose's ability to potentiate the β -cell response is its ability to suppress glucagon secretion from the α -cell. This function can also be measured using hyperglycemic clamps along with arginine [48, 90]. The ability of glucose to suppress the acute glucagon response is impaired in adults with type 2 diabetes and in those with prediabetes, indicative of impaired α -cell regulation [48, 91]. Knowledge in youth about the ability of glucose to suppress the α cell is lacking. This parameter will be quantified using the hyperglycemic clamp with arginine injection (AGRmin, minimum acute glucagon response) and will be analyzed as a secondary outcome in RISE.

2.7.2 Oral Tests of β - and α -cell Function and Insulin Sensitivity

The OGTT provides measures of islet function and has been used in large clinical trials for this purpose. The early insulin response (insulinogenic index) is an important determinant of glucose tolerance [34]. This response, when used in combination with a fasting measure of insulin sensitivity (1/fasting insulin, HOMA, or QUICKI) provides another estimate of β -cell function termed the "oral disposition index" (DIo) [40, 92]. However, the accuracy of HOMA in assessing changes in insulin sensitivity over time may not be as good as clamp techniques [93]. Using modeling approaches such as those developed by Mari et al. [94] and Cobelli et al. [95], it is possible to obtain a number of additional parameters of β -cell function and insulin sensitivity. In addition, using C-peptide levels and de-convolution techniques, insulin secretion rates can be calculated from the OGTT [94-96]. Finally, overall glucose tolerance can be calculated from the

glucose excursion during the test [97], providing a measure that is directly interpretable and applicable in the clinical setting.

Physiological glucagon suppression during an OGTT is an important determinant of glucose tolerance and provides an estimate of α -cell function. In individuals with type 2 diabetes, glucagon suppression is impaired [3, 46, 47], an abnormality that is improved with incretin-based therapy [21]. However, whether this change persists after withdrawal of therapy is unknown.

These OGTT-based measures will be performed in the study and their relationship with intravenous test-based measurements will be determined, both at baseline and following drug interventions in adults and youth. Previously we demonstrated that in obese youth, oral DI mirrors the DI calculated from two clamp experiments and is a simple surrogate estimate of beta cell function relative to insulin sensitivity [98].

2.8 Biomarkers of β -cell Function, α -cell Function, Insulin Sensitivity and Glucose Tolerance

It is often the case that biologic phenomena of interest are both difficult and costly to measure directly. This can be true of physiologic states such as β -cell function, but it is also true for time-dependent changes such as rates of progression to overt diabetes. In these instances we turn to biomarkers. An optimal biomarker is measured from a single biological sample (e.g., blood or urine) and is less costly, labor intensive and highly correlated with the result from the process under evaluation. However, a biomarker might be the result of combinations of blood tests, or measurements from other body fluids, or even measurements of other biological substances [99].

In RISE, treatments aimed at restoring or preserving β -cell function are being implemented and their effects determined using dynamic measures of β -cell function discussed above. This provides the opportunity to concurrently attempt to identify biomarkers to assess islet function in relation to the systemic metabolic state, and to predict how these change over time. The identification of such biomarkers is an important ancillary goal of the project since a practical application of strategies learned from this study will ultimately require a screening test to identify likely responders to the interventions.

2.8.1 Putative Diabetes Biomarkers

The detailed measures of β -cell function that we will be making provide an opportunity to identify biomarkers that can predict deterioration of β -cell function and/or response to interventions that can mitigate such deterioration. The identification of such biomarkers is an

important ancillary goal of the RISE Consortium. Because of budget constraints, the focus during this stage of the project will be on collecting patient specimens that can be used in the future for identification of biomarkers once the main outcomes of the study are known. We will collect samples that can be used to examine previously described peptide markers of diabetes risk (e.g., adiponectin, ferritin, ApoB, C-reactive protein, IL-2 receptor A [100-103]) and evolving markers of β -cell mass regulation (e.g., prolactin, DNA fragments and methylation, GLP-1, glucose-dependent insulinotropic peptide [GIP], HSP90 nucleic acids [104-108]). We will also collect serum samples that can be analyzed using genomic, micro-RNA, proteomic and metabolomics approaches comparing for example responders to non-responders to the study interventions.

3 STUDY DESIGN

3.1 Overview and Rationale

This document is specific for the **RISE Pediatric Medication Protocol** that three pediatric centers, with a contribution from the adult center at Indiana University, are performing together in youth with prediabetes or recent onset type 2 diabetes. This preliminary proof-of-principle study is a randomized trial comparing metformin alone to initial insulin glargine followed by metformin. The primary outcome is β -cell function, measured as defined below.

The RISE Pediatric Medication Protocol will involve 90 adolescents, age 10-19 years old, Tanner stage >1 as defined by breast stage >1 in girls, and testes >3 cc in boys. Volunteers will have prediabetes or recent onset (<6 months) type 2 diabetes and meet the following glucose-based parameters: HbA1c \leq 8.0% if treatment naïve, OGTT-based fasting plasma glucose \geq 90 mg/dl and a 2-hour post challenge glucose \geq 140 mg/dl. Youth receiving metformin will be included if their HbA1c is \leq 7.5% if on metformin for <3 months and \leq 7.0% if on metformin for 3-6 months.

Participants will be randomized to: (1) metformin alone for 12 months, or (2) initial insulin glargine for 3 months followed by metformin for 9 months. Volunteers will be recruited over a three-year period and followed for a total of 21 months following randomization. After baseline assessments and the run-in period, participants will be treated with active medication for 12 months. To determine if treatment has persistent benefits on β -cell function, subjects will be followed after discontinuation of treatment for a minimum of 3 months and up to 9 months if possible. Primary and secondary assessments will be performed at various time intervals while participants are receiving therapy and after medication discontinuation. The timing of the study, including interventions and testing, is shown in Figure 1.




Figure 1: Timing of interventions and outcomes testing for RISE Pediatric Medication Protocol

The chosen interventions are intended to test whether “resting” the β -cell (metformin alone) or further resting the β -cell (addition of insulin glargine) will retard the natural progression of prediabetes and type 2 diabetes by reducing secretory demand on the β -cell.

By including a 3-month washout period after which the primary outcomes will be assessed, the study will examine whether a beneficial effect of treatment persists beyond the period of active drug intervention. While shorter initial treatment intervals may be effective, the plan is first to determine the efficacy and durability of 12 months of treatment as a proof of principle. If no sustained effect is seen after 12 months of treatment, then it is very unlikely that a shorter treatment period would be efficacious. Complete end-of-study measures will be performed at the end of the 3-month washout period (15 months on study) and used for the primary analysis of the study. Where possible, β -cell function will be measured using an OGTT at 9 months post therapy (21 months on study) to evaluate whether treatment effects persist beyond the initial 3-month washout period. Full evaluation of the length of any durable response beyond these time points will require future studies designed specifically to address that question.

3.2 Primary Outcomes

The primary objective of the RISE Study is to evaluate the effects of randomized treatment on β -cell function, measured by hyperglycemic clamp techniques. Given that insulin and C-peptide are both used in quantifying β -cell function, each of them will be measured in certain or all tests in part to avoid the problem of co-linearity when performing the statistical analyses.

Two co-primary outcomes are specified:

- β -cell function measured as the **second phase response (steady-state of the hyperglycemic clamp)** (100-120 minutes of glucose infusion) [84]. This will be calculated

as mean C-peptide at steady state, adjusted for insulin sensitivity using the hyperglycemic clamp-derived measure of insulin sensitivity (glucose disposal rate/insulin: GDR/I).

- β -cell function measured as **AIRmax (arginine-induced acute insulin response at hyperglycemic glucose; β -cell secretory capacity)** [48]. This will be calculated as the incremental area under the C-peptide curve from 0-10 minutes following arginine injection at a plasma glucose ≥ 450 mg/dl, adjusted for insulin sensitivity measured by the hyperglycemic clamp.

Overall, for primary and secondary outcomes we will use the insulin sensitivity measured during steady state of the hyperglycemic clamp (glucose disposal rate [derived from the steady state glucose infusion rate] divided by steady state plasma insulin concentration 100-120 min) for adjustment of β -cell function measures [89].

The main analysis will evaluate the effect of study treatments to induce durable improvement in these primary outcome measures of β -cell function, by comparing glargine followed by metformin against metformin alone following a 3-month medication washout. The study will be analyzed under the intention to treat principle.

3.3 Secondary Outcomes

There are a number of pre-specified secondary outcomes. These include measures derived from the hyperglycemic clamp that are not specified as primary outcomes; measures derived from the OGTT; analyses related to treatment effect at the end of the 12 month active intervention period compared to pre-treatment baseline; and analyses related to various putative predictors of treatment outcome.

As presented in Figure 1, the timing of available secondary measures differs according to measurement methodology. Secondary outcomes will be evaluated by intention-to-treat analyses when evaluating effects of randomized study treatments.

3.3.1 β -cell Function and Glucose Tolerance

- (i) Hyperglycemic clamp-derived β -cell measures:
 - a. First phase insulin response (incremental insulin area from 0-10 minutes after initial glucose bolus)
 - b. First phase C-peptide response (incremental C-peptide area from 0-10 minutes after initial glucose bolus)
 - c. Disposition index derived from a and b, adjusting for insulin sensitivity using the hyperglycemic clamp-derived measure of insulin sensitivity (glucose disposal

rate/insulin: GDR/I)

- d. Second phase insulin response, with adjustment for insulin sensitivity using non-clamp-derived surrogate measures
- e. AIRmax response to arginine calculated using insulin concentrations and adjusted for insulin sensitivity

(ii) OGTT-derived β -cell measures:

- a. Early insulin response to oral glucose (insulinogenic index: Δ insulin from 0-30 minutes/ Δ glucose from 0-30 minutes [$\Delta I/\Delta G$])
- b. Early C-peptide response to oral glucose (parallel to (a))
- c. Oral disposition index (DI_o; insulinogenic index adjusted for insulin sensitivity)
- d. Modeled parameters of β -cell function (β -cell glucose sensitivity, rate sensitivity and potentiation factor; static, dynamic, and total β -cell glucose sensitivity)
- e. Ratios of incremental insulin/glucose (iAUC_{ins}/iAUC_g) and C-peptide/glucose (iAUC_{cp}/iAUC_g) responses from 0-120 minutes
- f. Incremental glucose (iAUC_g) response as a measure of glucose tolerance
- g. 2-hour glucose
- h. GLP-1 total and incremental response to oral glucose load (samples will be collected, and measured for this analysis if funding allows)

(iii) Fasting measures:

- a. Glucose
- b. Proinsulin/insulin ratio
- c. HOMA %B (using the Oxford calculator)
- d. HbA1c

3.3.2 α -cell Function

A. Hyperglycemic clamp-derived measures:

- a. Glucagon suppression in response to sustained hyperglycemia during the clamp (the decrement in glucagon concentration from baseline to nadir value at 100-120 minutes)
- b. Acute glucagon response to arginine (the incremental increase in glucagon concentration from pre-arginine baseline for the 10 minutes after the arginine injection)

B. OGTT-derived measures: integrated glucagon response from 0-120 minutes

C. Fasting measures: glucagon

3.3.3 Insulin Sensitivity

- (i) Hyperglycemic clamp-derived measures: glucose disposal rate at steady state (100-120 minutes) divided by ambient insulin concentrations
- (ii) OGTT-derived measures:
 - a. Matsuda index
 - b. Model-derived insulin sensitivity
- (iii) Fasting measures:
 - a. $1/\text{fasting insulin}$,
 - b. HOMA-S (using the Oxford calculator),
 - c. QUICKI

3.3.4 Blood and Urine Biomarkers

- (i) Glycemic control: HbA1c (baseline predictor, and as a time-dependent treatment outcome)
- (ii) Adipokines/inflammatory markers: adiponectin; others contingent on funding (see list above in Section 2.8.1)
- (iii) Non-esterified fatty acids
- (iv) Renal/vascular: urinary albumin/creatinine ratio at baseline (measures at other time points contingent on funding)

3.3.5 Physical Measures

- (i) Physical measures: blood pressure, body weight, body mass index, waist and hip circumference.

3.4 Treatments

3.4.1 Three-week Placebo Run-in Phase

Prior to randomization, eligible volunteers will participate in a 3-week run-in period. They will be instructed by study staff in proper injection technique and will receive three weeks placebo tablets. Participants already on metformin will be provided metformin at their entering dose while treatment naïve patients will receive placebo capsules. At the end of the placebo-run in period, they will return any unused medication which will be counted to assess adherence. Participants taking <80% of the medication will be excluded from further participation, and if they were previously on metformin, returned to their home metformin medication.

Those who have been compliant with medication use ($\geq 80\%$) will be eligible to participate and will undergo the baseline study procedures. Once these are completed, and if willing to

undergo these tests repeatedly as required by the study, they will be randomized to one of the treatment arms and will enter the active treatment phase. In addition, after completing the first set of study procedures, they will receive instruction in lifestyle modification, including individualized instruction on weight loss, exercise and diet.

3.4.2 Twelve-month Active Treatment Phase

Participants will be randomized to one of the two interventions. Participants will be seen every three months throughout the study and will be given three months of medication at a time during the active treatment phase. Study staff will monitor compliance by auditing returned medication every three months. Participants who have diabetes will be required to perform home blood glucose monitoring.

Participants randomized to metformin monotherapy or initial insulin glargine followed by metformin will not be masked to the intervention.

Metformin is approved for treating type 2 diabetes in youth and will be used according to the label. Investigational New Drug (IND) applications have been ruled exempt for the use of metformin in youth with prediabetes and for the use of insulin glargine in youth with prediabetes and type 2 diabetes. For study procedures performed during the active phase of treatment, study medications will be withheld on the morning of testing.

3.4.3 Metformin

Metformin use is the same in all treatment groups that use it. To minimize non-compliance due to gastrointestinal side effects, patients who are not already on metformin will be titrated over a maximum of eight weeks from a starting dose of 500 mg once daily to a maximum dose of 1000 mg bid. Participants already on metformin will have their dose titrated similarly to a maximum dose of 1000 mg bid. Participants will remain on the maximum tolerated dose of metformin throughout the study. If participants are unable to tolerate metformin they will continue in the study but will not take the medication.

3.4.4 Insulin Glargine Followed by Metformin

Insulin will be titrated over a period of one month based on daily self-blood glucose monitoring to achieve a fasting blood glucose of 80-90 mg/dl without hypoglycemia, and then continued with dose adjustments to maintain the fasting glucose in this range.

Insulin glargine has been shown to be safely titratable in adults with prediabetes and established type 2 diabetes to achieve fasting glucose concentrations of <95 mg/dl without a clinically significant increase in recurrent or severe hypoglycemia [64]. Following 3-months of

insulin treatment, insulin glargine will be discontinued and metformin will be commenced and titrated as above.

3.4.5 Medication Wash-out and Post-treatment Follow Up

Following the completion of the intensive re-assessments (hyperglycemic clamp and OGTT) after 12 months of the intervention, study medications will be stopped and the participants will continue to be followed off medications, for a minimum of 3 months and up to 9 months, depending on the time of randomization within the 5-year study period. At the end of the first 3 months off treatment (i.e., 15 months after randomization), the hyperglycemic clamp and OGTT will be repeated to determine the durability of the effects of the active interventions on β - and α -cell function. Although it is unlikely in this study population, participants may experience deterioration in β -cell function during this 3-month wash out period as determined by elevation in HbA1c, development of urinary ketones or symptoms of hyperglycemia, and require rescue therapy. Criteria for rescue, and protocol-specified rescue therapy, are described below (see Section 7.4). Participants who do not require rescue will undergo the final clamp and OGTT procedures at the end of the 3-month washout period. They will then continue to remain off study medications and retesting will occur 9-months following discontinuation of the intervention (i.e., 21 months after randomization). The rescue protocol will be utilized, as needed, during this last 6-month follow-up period. Following the complete 9-month washout period, patients will be referred to their primary care provider for further follow up and decisions regarding appropriate treatment.

3.4.6 Rescue

The approach to rescuing a participant with severe hyperglycemia is described in Section 7.4.

3.5 Inclusion Criteria

1. Fasting plasma glucose ≥ 90 mg/dl *plus* 2-hour glucose ≥ 140 mg/dl on 75 gm OGTT *plus* laboratory-based HbA1c $\leq 8.0\%$ if treatment naïve. There is no upper limit for the 2-hour glucose on OGTT. In those taking metformin laboratory-based HbA1c must be $\leq 7.5\%$ if on metformin for < 3 months and $\leq 7.0\%$ if on metformin for 3-6 months.
2. Age 10-19 years
3. Pubertal development Tanner stage > 1 as defined by breast stage > 1 in girls, and testes > 3 cc's in boys.
4. Body mass index (BMI) $\geq 85^{\text{th}}$ percentile but ≤ 50 kg/m²

5. Self-reported diabetes <6 months in duration
6. Treatment with metformin for <6 months preceding screening

3.6 Exclusion criteria

1. Underlying disease likely to limit life span and/or increase risk of intervention or an underlying condition that is likely to limit ability to participate in outcomes assessment
2. An underlying disease that affects glucose metabolism other than type 2 diabetes mellitus
3. Taking medications that affect glucose metabolism, or has an underlying condition that is likely to require such medications
4. Treatment with insulin for >1 week preceding screening
5. Active infections
6. Renal disease (serum creatinine >1.2 mg/dl) or serum potassium abnormality (<3.4 or >5.5 mmol/l)
7. Anemia (hemoglobin <11 g/dl in girls, <12 g/dl in boys) or known coagulopathy
8. Cardiovascular disease, including uncontrolled hypertension defined as average systolic or diastolic blood pressure > 99 percentile for age or >135/90, despite adequately prescribed antihypertensive medications. Participants must be able to safely tolerate administration of intravenous fluids required during clamp studies.
9. History of conditions that may be precipitated or exacerbated by a study drug:
 - a. Serum ALT more than 3 times the upper limit of normal
 - b. Excessive alcohol intake
 - c. Sub-optimally treated thyroid disease
 - d. Treated or untreated seizure disorder
10. Conditions or behaviors likely to affect the conduct of the RISE Study
 - a. Participant and/or parents unable or unwilling to give informed consent
 - b. Participant and/or parents unable to adequately communicate with clinic staff
 - c. Another household member is a participant or staff member in RISE

- d. Current, recent or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in RISE
- e. Weight loss of $\geq 5\%$ of body weight in the past 3 months for any reason other than post-partum weight loss. Participants taking weight loss drugs or using preparations taken for intended weight loss are excluded.
- f. Likely to move away from participating clinics in next 2 years
- g. Current (or anticipated) pregnancy and lactation.
- h. A pregnancy that was completed less than 6 months prior to screening.
- i. Breast feeding within 6 months prior to screening.
- j. Women of childbearing potential who are unwilling to use adequate contraception
- k. Major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of RISE

11. Additional conditions may serve as criteria for exclusion at the discretion of the local site.

Further details pertaining to exclusion criteria are specified in the Manual of Procedures.

3.7 Randomization

Randomization is stratified by clinical center and by prediabetes vs. diabetes status to ensure balance among the treatment groups with respect to anticipated differences in the participant populations. For each clinical center, the Coordinating Center (CoC) will generate two randomization schemes using a permuted block design. In this way, sample sizes across the two treatment arms will remain relatively equivalent as the trial progresses. The clinical center staff will use a computer-based system to input eligibility data and receive a random treatment assignment.

3.8 Masking

During the run-in period, participants who are drug-naive will take metformin placebo. All participants will be taught how to perform injections to assess compliance with possible study medications. Placebo injections will not be used during the active treatment phase – i.e., the treatment assignment will not be blinded.

4 RECRUITMENT

4.1 Recruitment

The primary source of participants for the RISE Study is the active patient population of the study sites and their usual referral sources. Participants will be recruited over a three year period. Recruitment techniques include notices placed on bulletin boards at the medical centers, newspaper and radio advertisements and public service announcements, referral from colleagues, and screening from the investigators' clinics. Prescreening of electronic and clinical medical records is strongly encouraged to reduce available screen failure rates. Selection is based solely on the participant's ability to meet the criteria stated in the protocol, his/her willingness to participate in the study, and his/her parents' willingness to have their child participate. Site-specific recruitment strategies are developed by each local study team.

The performance of the clinical centers in recruiting and retaining eligible RISE participants will be monitored by the CoC and the Recruitment and Retention Committee. Monthly recruitment summaries will be issued throughout the recruitment and randomization period detailing the number of potential participants screened, number randomized, and reasons for ineligibility or of refusal to participate by clinical center. The reasons for ineligibility or refusal to participate will be compared among the clinical centers, and if large differences are found, explanations for these differences will be sought. If the randomization rate falls below the desired number of participants per month, data on reasons for ineligibility and refusal will be used to try to identify strategies that would increase the randomization rate. Site visits may be needed and assistance will be offered to clinical centers struggling with recruitment efforts.

4.2 Description/Justification of the Target Study Population

Preliminary screening will be done to enrich the yield of individuals who have prediabetes or type 2 diabetes. These individuals will be invited for initial field testing using clinical, HbA1c and/or OGTT criteria. Youth who are highly predisposed to develop type 2 diabetes include, but are not limited to, those with:

- Known impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG)
- Overweight or obesity (BMI $\geq 85^{\text{th}}$ percentile)
- Age ≥ 10 years
- First degree relative with type 2 diabetes
- Sedentary lifestyle
- Those with low HDL cholesterol or high triglycerides, hypertension (i.e., "the metabolic syndrome")

- Certain racial and ethnic groups (e.g., Non-Hispanic Blacks, Hispanic/Latino Americans, Asian Americans and Pacific Islanders, and American Indians and Alaska Natives)
- Teenage women who had gestational diabetes, or who have had a baby weighing 9 pounds or more at birth
- Offspring of mothers who had diabetes while pregnant, including gestational diabetes
- Adolescent girls with polycystic ovary syndrome (PCOS)

The lifetime risk for type 2 diabetes among these groups is substantially higher than that seen in the general population. Further, the presence of more than one of these factors enhances the likelihood of development of type 2 diabetes to an even greater degree than does the presence of any single factor noted above. A recent evaluation of diabetes risk attempted to quantify the value of well-known diabetes associated risk factors [109].

Patients who are in these high risk categories will be invited for a screening visit during which they will undergo a 75 gram glucose tolerance test and have HbA1c measured. Of those who undergo a 75 gram OGTT and the lab-based HPLC HbA1c, we expect that approximately one-third of individuals will meet study enrollment criteria, i.e., will have a fasting plasma glucose ≥ 90 mg/dl *plus* a 2-hour glucose ≥ 140 mg/dl *plus* a laboratory-based HbA1c $\leq 8.0\%$ if treatment naïve [in those taking metformin, HbA1c must be $\leq 7.5\%$ if on metformin for < 3 months and $\leq 7.0\%$ if on metformin for 3-6 months]. There is no upper limit for the 2-hour glucose on OGTT.

4.3 Informed Consent

Written informed consent will be obtained prior to initiation of any study-related activities. The informed consent process will be performed in a quiet setting prior to the initiation of any study procedures. The subject and his/her parents will be provided adequate time to read and understand the written consent and ask questions as necessary. If they choose, they may take additional time to discuss the study with family and/or physicians outside the clinic setting. Consent documents are not signed until volunteers demonstrate adequate understanding of all aspects of the study and consent process. A copy of the consent will be given to the subject. There will be two consent forms – one for the Screening stage and one for the Intervention stage. Model consent forms are provided in Appendix A.

In the event that a significant protocol change occurs, the informed consent documents will be adjusted appropriately and sites will submit the revised documents to their Institutional Review

Board (IRB) for approval. Local IRBs will determine whether it is necessary to re-consent participants.

Sites will submit to the CoC stamped IRB approval letters and current copies of all consent forms prior to study initiation, annually thereafter, and at the time of any protocol changes. These records will be maintained by the CoC as a central archive.

4.4 Staged Screening and Randomization

Screening for enrollment in RISE will be conducted in a stepwise manner involving completion of a screening visit and a 3-week run-in period at the end of which baseline measurements, including the OGTT and hyperglycemic clamp, will be performed. Screening proceeds from least invasive, most easily obtained criteria to the most demanding procedures. Once a participant is determined to be ineligible, the screening process stops.

The staged screening process is intended to accomplish the following:

- identify potentially eligible participants for RISE,
- verify eligibility of participants,
- accomplish the objectives of the informed consent process,
- complete a run-in period,
- establish a research cohort likely to complete the study and adhere to the medication schedule and the complex testing of β -cell function and related measures, and
- randomize participants into RISE.

Complete definitions and procedures are in the Manual of Procedures.

All steps below will be conducted if and only if the parents of the participating minor and/or the participating individual provides written informed consent for participation in RISE. If for any reason the participant and his/her parents wish not to participate in any of the activities and experimental procedures outlined in the informed consent, the consent form will not be signed and no further data collection or biological testing will be conducted. If the participant and his/her parent agree to participate in RISE, he/she will provide written documentation by signing the consent form. If for any reason the participant wishes to withdraw from the study at any time, there will be no pressure upon the participant to continue and withdrawal will be documented.

Staged screening and enrollment includes the following steps:

1. *Initial Contact*: This contact aims to identify individuals who are predisposed to develop type 2 diabetes by virtue of having one or more risk factors (Section 4.2). Potential

participants are seen and given detailed information about RISE, including research interventions, randomization, masking, test procedures, risks and benefits, and the eligibility process. If they give oral and/or written consent/assent, they are first interviewed and records are reviewed for personal and medical history. If they pass these eligibility criteria, they will be invited to attend the clinic for a full screening visit where a complete history will be taken and lab tests performed.

2. *Screening*: If the participant meets initial inclusion criteria, he/she will return for a physical examination, full eligibility testing, and instruction in taking medication for the placebo run-in phase. A fasting 75 gram OGTT will be performed. In order to qualify for further consideration, the fasting glucose must be ≥ 90 mg/dl, 2-hour glucose must be ≥ 140 mg/dl and the laboratory-based HbA1c must be $\leq 8.0\%$ if treatment naïve [in those taking metformin, HbA1c must be $\leq 7.5\%$ if on metformin for < 3 months and $\leq 7.0\%$ if on metformin for 3-6 months].
3. *Run-in*: If the above criteria are met, the participant will be asked to undergo a 3-week run-in period. The run-in period (described in Section 3.4.1) allows staff to evaluate a patient's suitability for RISE. At the end of the run-in, clinic staff will assess the patient's adherence to medication taking, assess final eligibility criteria which will include a repeat POC HbA1c that must meet the same criteria as at the initial contact, and determine whether the patient should be randomized to RISE.
4. *Final screening visit and randomization*: If the participant is eligible, informed consent/assent is obtained, baseline data including at laboratory HbA1c are collected and the OGTT and hyperglycemic clamp are performed. If after completion of these studies the participant is willing to be randomized, the participant is randomly assigned to a treatment group.

If during the screening process the participant is deemed ineligible, but his/her condition changes during the recruitment period (e.g., the participant has uncontrolled hypertension that becomes adequately treated or an active infection that has resolved), he/she may be reconsidered for inclusion if he/she maintains eligibility for three months. Screening procedures are re-initiated and the participant must meet all eligibility criteria at the time of re-enrollment.

A minimal amount of data is recorded on participants who fail screening (such as age group, gender, race/ethnicity, diabetes duration) for purposes of comparing participants versus nonparticipants.

5 PATIENT MANAGEMENT

5.1 Description of RISE Research Facility Treatment(s)

Study treatment interventions are described in detail above (Section 3.4). Glucose management (including study medications) will be provided free of charge to RISE participants. In accordance with standards of care, HbA1c will be monitored every 3 months. Procedures to be followed for rising HbA1c levels are described in Section 7.4. Beyond the treatment of the glucose-aspect of prediabetes and diabetes care, the research study will not assume responsibility for the medical care of the participant. Non-glucose aspects of diabetes care (e.g., blood pressure, lipids, obstructive sleep apnea) and non-diabetes related medical problems will be referred to the participant's primary care provider. When a potential treatment could affect the study's outcome(s), the RISE physician may discuss the choices with the participant's primary care provider. With the participant's permission, RISE Study lab results will be shared with the provider. For those participants who do not have a primary care provider, the study staff will help find appropriate medical care.

5.2 Drug Distribution

Study medications will be distributed to individual study centers. Individual centers will organize and maintain inventory, in cooperation with their investigational or research pharmacy. Sites will ensure that sufficient medication is always on hand to allow medication distribution for the next 3 month period. This includes medications required for the next 6 randomized enrollees (i.e., on average 3 initial distributions for each of the 2 treatment arms) plus all of the upcoming distributions to enrolled participants who will be returning within 3 months. Expiration dates of all medications will be double checked and documented on arrival at the study center and at the time of distribution to participants to ensure that the provided supplies will not expire during the current treatment interval.

Except for the placebo (metformin) distributed during the 3-week run-in period, medication will be dispensed to participants in 3 month quantities, and bottles/boxes/containers/syringes will be collected from participants at the quarterly visits to allow compliance assessment by pill counting or residual volume estimation for liquid medications. Subsequent treatment supplies will be provided with each quarterly visit.

Non-study medications will not be provided through the clinical centers.

5.3 Adherence Measures

Adherence will be documented, monitored, and addressed as part of participant care and

management and to monitor whether procedures are being implemented and followed equivalently across all sites. Adherence refers to all study procedures – not only taking the prescribed amount of study drug, but also attending scheduled study visits and completing procedures at those visits. The goal is to maintain high levels of adherence in all participants and across all sites. Primary adherence measures will address visit attendance and completion of study procedures, medication adherence, and adherence to recommended home glucose monitoring. Medication adherence will be assessed on a quarterly basis, by pill counting or by residual volume estimation of glargine. Participants will be instructed to bring all study medications (including empty bottles/vials/pens/syringes) to study visits.

5.3.1 Placebo Run-in

Metformin/placebo compliance will be assessed by pill counting as a percentage of the expected pills that were taken. Active metformin will be provided to subjects already on metformin at the dose they were currently taking, and compliance assessed by pill counting as a percentage of the provided expected pills that were taken.

5.3.2 Insulin

Insulin will not be blinded in RISE. Insulin use will be prescribed to assigned participants only for the first 3 months of their participation. The projected volume consumed cannot be generalized, but will need to be calculated for each participant based on their recorded dosing titration and their final dosing. The dosing administration record will be used to assess compliance, and confirmed with a residual volume assessment and assessment of syringes remaining.

5.4 Retention

Retention refers to efforts to prevent participant dropout or withdrawal from the study. It is critically important to successfully engage and retain participation over the course of the trial. For purposes of sample size estimation, we have predicted withdrawal rates of 10% during the 15-months of primary data collection and have adjusted sample size to meet study requirements. However, lower rates of attrition are desirable.

The Study Coordinator at each site is primarily responsible for monitoring participant attrition and initiating team conferences for retention strategies or dropout recovery rates. Individual sites will develop strategies to enhance retention specific to their locale and specific population. Activities at both the national and local level will be coordinated to maximize retention and minimize attrition. Subjects missing scheduled visits will be contacted within 24 hours of the scheduled visit to reschedule and discuss strategies to improve compliance. If the

site is unable to contact the subject, the site will send a certified letter to the participant to encourage continuation in the trial even if they no longer wish to take the study medication. At the local level, study staff will implement efforts to personalize the study (mailing out personal notes, birthday cards, etc.).

Attrition is monitored regularly by the CoC and the Recruitment and Retention Committee. An attempt is made to collect data on the reason for leaving the study in the case of a participant who withdraws. Assistance is offered to any site with a higher than average attrition rate. Sites will also be encouraged to share their ideas and experiences via regular communication and conference calls for Study Coordinators. The CoC will prepare monthly reports on visit completion, compliance with the RISE Study protocol and participants on inactive follow-up.

6 DATA COLLECTION

6.1 Main Study Procedures

The timing of major study procedures during the different phases of the study is illustrated in Figure 1. Outcomes using hyperglycemic clamp procedures will be obtained at baseline, at the end of 12 months of treatment, and after a 3-month washout period (i.e., 15 months post randomization). Additional outcomes will be obtained from the OGTT concurrent with the hyperglycemic clamp procedures, and also at additional time points -- at 6 months on therapy, and at 9 months after stopping therapy (i.e., 21 months post randomization). Blood and urine samples for planned measures will be collected at these visits, along with extra blood and urine samples that will be stored for future analyses. Further details on these measures are provided below, and are summarized in Figure 1 above. All procedures and measures will be conducted by centrally trained and certified staff.

6.1.1 Fasting Blood and Urine Samples

HbA1c will be measured and fasting blood and urine samples will be collected at each 3-monthly study visit. Aliquots of fasting blood and urine will be stored for subsequent measurement of biomarkers. A blood sample for DNA will be collected at randomization for subsequent genetic analysis should funding become available. A hemoglobin and urine pregnancy test will be performed at baseline, 12 and 15 months to rule out anemia and pregnancy prior to each clamp procedure; ALT and creatinine will be measured at baseline and 6 months. Pregnancy tests will also be done at any time if pregnancy is suspected.

6.1.2 Oral Glucose Tolerance Test (OGTT)

Participants will come to the clinical research testing facility in the morning following a 10-12

hour overnight fast. They will drink 75 grams of an oral glucose solution (centrally provided from a single manufacturer) over ≤ 5 minutes. Blood samples will be obtained at -10, -5, 10, 20, 30, 60, 90, 120, 150 and 180 min relative to glucose ingestion. OGTT procedures will be performed at baseline, at 6 and 12 months on active treatment, and 3 and 9 months after stopping treatment, i.e., 15 and 21 months after randomization.

6.1.3 Hyperglycemic Clamp

Hyperglycemic clamps (goal steady state glucose levels of 200 mg/dl and >450 mg/dl) will be performed at baseline, 12 months post randomization while on active treatment, and 15 months post randomization (i.e., after 3 months of washout). Participants will return to the testing facility to undergo the clamp after a 10-12 hour overnight fast. The clamp will be performed on a day separate from the OGTT. The clamp can be performed on the day immediately following the OGTT, but the OGTT will not be performed on the day immediately following the clamp.

The clamp procedure will incorporate 3 main sets of blood sampling for the planned outcome measures: first phase (0-10 minutes); second phase (100-120 minutes); and maximal stimulated responses (from 10 minutes before arginine until 10 minutes after arginine). To guide the clamp, a small volume of arterialized venous blood will be obtained at 5-min intervals throughout for clamp for measurement of plasma glucose concentration and titration of the dextrose infusion.

For the OGTT and clamp measures, participants will be asked to refrain from vigorous exercise and tobacco use for 24 hours before the baseline measures. Study medications will be withheld the morning of testing.

6.2 Eligibility Screening Measurements

Screening and run-in procedures are listed in Table 1.

Prescreening (initial contact): Prescreening for potential eligibility can be done using a single random capillary (finger stick) blood sample for measurement of HbA1C with a POC instrument or a lab HbA1c as a guide to help decide who to screen. In addition, a screening questionnaire that includes a focused medical history, anthropometric and blood pressure measures must also indicate that they meet initial eligibility criteria. *Screening:* Participants who meet pre-screening eligibility criteria will present to the study center for formal screening to undergo a standard 2-hour 75 gram OGTT, with samples analyzed in the central laboratory. Only fasting and 2 hour post-load samples will be obtained. A laboratory-based HbA1c must be $\leq 8.0\%$ if treatment naïve [in those taking metformin, HbA1c must be $\leq 7.5\%$ if on metformin for <3

months and $\leq 7.0\%$ if on metformin for 3-6 months], fasting glucose must be ≥ 90 mg/dl and 2-hour glucose ≥ 140 mg/dl for eligibility in RISE. Eligibility lab tests will also be performed, including electrolytes, TSH (when clinically indicated), triglycerides, creatinine, ALT, GAD and ICA-512 antibodies, hemoglobin, and urine pregnancy test.

Placebo run-in: Participants meeting eligibility criteria will be instructed to begin the 3-week placebo run-in. Participants who have $< 80\%$ adherence with study medications during this run-in phase will be withdrawn from the study and no further study procedures will be performed. Participants who are adherent with $\geq 80\%$ of study medication during run-in will proceed to baseline study measurements. Participants will be asked demographic and medical history information.

Table 1: Data Collection During Screening and Run-In Procedures

STEP	TEST / PROCEDURE	COMMENTS
1) Pre-screening	Optional Screening HbA1C (POC or recent lab value)	Continue screening if $\leq 8.2\%$ if treatment naïve, $\leq 7.7\%$ if on metformin for <3 months and $\leq 7.2\%$ if on metformin for 3-6 months
	Screening questionnaire	Initial review of eligibility
	Height, weight and BP	Initial screening for eligibility
2) Screening	HbA1c (central lab), 75 gram OGTT (central lab); glucose at 0 and 120 min	Eligibility HbA1c $\leq 8.0\%$ if treatment naïve, $\leq 7.5\%$ if on metformin for <3 months and $\leq 7.0\%$ if on metformin for 3-6 months fasting glucose ≥ 90 mg/dl; 2-h glucose ≥ 140 mg/dl
	Eligibility labs*	Laboratory eligibility criteria
	Demographics, medical history, medications and physical examination	Eligibility evaluation
3) Run-in	Placebo dispensed	Initiate run-in
	Evaluate	Determine eligibility for randomization

*Eligibility labs: electrolytes, TSH[†], triglycerides, creatinine, ALT, GAD and ICA512 antibodies, hemoglobin.

[†]TSH should be assessed as part of trial screening procedures in the following settings: 1) reported use of anti-thyroid medication, 2) reported use of thyroid hormone, 3) reported history of thyroid disease or 4) clinical suspicion of thyroid disease on history and physical.

6.3 Baseline and Post-Randomization Measures

Measurements to evaluate safety, adherence, and outcomes are summarized in Table 2. The outcomes, derived from hyperglycemic clamp procedures, will be measured at baseline, 12 months (end of treatment), and 15 months post randomization (end of washout). OGTT outcomes measurements and blood sampling for other outcomes will be performed at baseline, 6 and 12 months following randomization (on treatment) and then at 15 and 21 months (off treatment, provided that HbA1c levels remain within the acceptable range while off treatment). Hyperglycemic clamp and OGTT outcomes measures are described in detail

above. Other measurements are discussed below.

Table 2: Timeline of Outcomes, Safety Testing, and Adherence Measures

	Baseline/ Pre random- ization	Post Randomization Month						
		3	6	9	12	15	18	21
Physical								
Height	x	x	x	x	x	x	x	x
Weight	x	x	x	x	x	x	x	x
Waist / Hip circumference	x				x	x		x
Blood pressure	x	x	x	x	x	x	x	x
Outcomes								
Hyperglycemic clamp & AIR _{max}	x				x	x		
OGTT	x		x		x	x		x
HbA1C	x	x	x	x	x	x	x	x
Questionnaires	x							
Sleep (Cleveland Adolescent Sleepiness Questionnaire, Sleep Disturbance Scale for Children)	x							
Biomarkers	x		x		x	x		x
Stored Specimens								
DNA	x							
Plasma / Serum	x		x		x	x		x
Urine	x		x		x	x		x
Safety								
SMBG for those with diabetes	x	x	x	x	x	x	x	x
Hemoglobin (local measure)	x				x	x		
Blood chemistries**(local measure)	x		x					
Adverse events	x	x	x	x	x	x	x	x
Pregnancy test ⁺ (local measure)	x				x	x		
Medication adherence	x	x	x	x	x			

** fasting serum ALT and creatinine +pregnancy tests can also be done as needed based on symptoms and menstrual history

6.3.1 Physical Measures

Height will be measured with a stadiometer. Weight will be measured with a calibrated electronic scale. Waist and hip circumferences will be measured at the mid-point between the

iliac crest and the lowest rib (waist), and at the top of the femur (hip) with the participant standing upright.

6.3.2 Sleep Assessments

During screening, participants will complete the Cleveland Adolescent Sleepiness Questionnaire and the Sleep Disturbance Scale for Children for analysis of self-reported sleep-related measures as potential predictors of response to treatment.

6.3.3 Safety Measures

The study will provide blood glucose monitors and strips for use during the study. Participants with diabetes will be instructed to monitor and record fasting blood glucose daily, in the morning, and as otherwise instructed for safety monitoring. Routine local laboratory studies consisting of a hemoglobin or hematocrit, serum ALT and creatinine, and a urine pregnancy test will be collected for evaluation of anemia and liver and kidney function and to rule out pregnancy at baseline; serum ALT and creatinine will be repeated at 6 months during treatment, and a hemoglobin or hematocrit and urine pregnancy will be repeated at 12 and 15 months to rule out anemia or pregnancy before the insulin clamp. Adverse events (AE) will be surveyed at each visit using a standardized questionnaire.

6.3.4 Participant Protocol Adherence

Pill counts will be performed at each visit from run-in to the end of the treatment period. Similarly, glargine pen residual volume will be determined. Participants will be asked to bring all medications to all visits. For participants with diabetes and for those on glargine, self monitoring blood glucose (SMBG) data will be reviewed at each visit (every 3 months) or more frequently if needed.

6.4 Visit Windows

Participants will be encouraged to complete visits within a 1-2 week window before or after the scheduled study visit. All participants will have a visit calendar generated at the time of randomization to assist in keeping visits scheduled as required. The specific actions recommended when a visit window is missed will be described in the MOP.

7 SAFETY / HUMAN SUBJECTS PROTECTION

This trial will be conducted in compliance with the protocol and all applicable regulatory requirements. All participating clinical sites must have a Federal-wide Assurance with the Office for Human Research Protections. All sites will follow HIPAA regulations.

Prior to study initiation, the protocol and the informed consent documents will be reviewed and approved by the IRB at each participating clinical site and by an independent Data and Safety Monitoring Board (DSMB). Any amendments to the protocol or consent materials must be approved by the DSMB and the IRBs before implementation.

7.1 Data and Safety Monitoring Board (DSMB)

A DSMB comprised of appropriately qualified and conflict-free independent experts is appointed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and provides input to the Institute. Board members are chosen by the NIDDK without consultation with the study investigators. The purpose of the Board is to assure independent review as to whether study participants are exposed to any unreasonable risk because of study participation, and to monitor study progress and integrity. In addition to safety monitoring, the Board can review unblinded study data and make recommendations for early termination of studies for achieving an end point or for futility. Before any of the RISE studies can begin, the DSMB, in addition to the local IRBs, must approve the protocol. Any subsequent major changes to the protocol must also be approved by the DSMB and IRBs.

Following each DSMB meeting, a summary of DSMB recommendations is provided to the IRB of each participating clinical center and other institutional monitoring committees/boards as needed.

7.2 Data and Safety Monitoring Plan

7.2.1 Informed Consent

Written informed consent will be obtained prior to initiation of any study-related activities. The informed consent process will be conducted by qualified study personnel. All participants must read, sign and date a consent/assent form as appropriate (consent for participants age 18 and above, assent signed by participants/consent signed by parents for participants under age 18) prior to participation in any stage of the study. The informed consent/assent will be revised and participants re-consented whenever there is new, clinically significant information regarding the safety of the interventions, when a relevant protocol amendment is approved, or when any new information becomes available that may affect an individual's participation in the study. At

any time during the study, participants will have the option to withdraw from participation without repercussion. In the event that a participant withdraws, study medication will no longer be provided.

7.2.2 Safety Review Plan and Monitoring

- A. Justification of Sample Size – See Section 9.3.
- B. Stopping Rules – The DSMB may suggest terminating a study arm at any time for safety or efficacy reasons. Details of interim analysis plans and stopping rules can be found in Sections 9.4 and 9.5.
- C. Safety Monitoring Committee and Safety Review Officer – The study will appoint an internal Safety Monitoring Committee (SMC) which will review AEs or other safety-related problems sent to them from the field. The RISE SMC will review AEs in a blinded manner. An external Safety Review Officer will evaluate any serious adverse events (SAE) where the SMC is not in agreement about whether the event is related to study drug as well as certain specified SAEs of concern (details in the MOP). The Safety Review Officer will not be blinded to study intervention.
- D. Safety Review Plan – The DSMB will meet at least twice yearly either in person or by conference call to review study progress and safety as described in Section 7.1.

7.2.3 Confidentiality

- A. Protection of subject privacy – Participants are identified within the study only by their RISE Participant ID. No personal identifiers are used in any data collection.
- B. Database Protection – All files are stored in a locked cabinet at the clinical centers, and data are entered into a secure, password-protected website maintained by the CoC. The CoC holds no personal identifiers and stores the data on its enterprise server accessible only by approved staff. At the end of the study, all records will be kept in a secure locale for a period dictated by local IRB and Institutional policies as well as FDA regulations, whichever is longest.
- C. Confidentiality During AE Reporting – AEs and SAEs are recorded on data collection forms and reported to the CoC without personal identifiers. Identifiers on accompanying documents (such as medical records) are removed before submission to the CoC and any subsequent transfer to the Safety Monitoring Committee and/or Safety Review Officer.

7.3 Expected Side Effects

The RISE Pediatric Study will use the following medications: metformin and insulin glargine.

Metformin: Known adverse effects associated with metformin are primarily gastrointestinal (diarrhea, nausea, vomiting, abdominal bloating, flatulence, anorexia), hematologic (reduced vitamin B12 levels and, rarely, megaloblastic anemia), and the rare possibility of lactic acidosis. The risk of lactic acidosis associated with metformin use will be minimized by (1) monitoring liver transaminases, (2) monitoring renal function, and (3) temporary discontinuation of metformin before radiologic studies involving the injection of contrast dye, surgical procedures requiring reduced fluid intake, and serious illness that might be associated with hypoxia, dehydration, or shock. In the TODAY study, among approximately 230 youth on metformin alone, there was no severe hypoglycemia (unpublished data).

Insulin glargine: The side effects of insulin glargine include hypoglycemia and slight weight gain. Participants will be counseled about the possibility of weight gain while on insulin therapy and given dietary counseling and resources. In addition, the metformin phase following the insulin should also help decrease weight gain. The occurrence of hypoglycemia will lead to insulin dose adjustment at the discretion of the investigator. Glargine does not peak, unlike NPH insulin, and therefore has much lower risk of hypoglycemia, especially overnight. In addition, due to its lack of a peak, subjects can safely skip meals or fast with glargine. Participants on insulin will perform SMBG to minimize the risk of hypoglycemia. In the ORIGIN trial, weight gain in the glargine group was on average only 1.6 kg after a mean glargine use of 6.2 years, and hypoglycemia was minimal [64]. In the TODAY study, of 699 pediatric subjects where much higher doses of insulin were used, there was only 1 episode of severe hypoglycemia which had no sequelae (unpublished data).

7.4 Risk Management

Glucose management (including study medications) will be provided free of charge to RISE Study participants while participating in the study. Participants will receive training about the proper use of hypoglycemic medications as well as education about the symptoms, causes and response to episodes of hyper- and hypoglycemia. Participants who develop symptomatic hypo- or hyperglycemia, or experience any side effects of medications or study procedures will be instructed to call the clinical site. The following procedures will be implemented to minimize risk to participants:

- *Hyperglycemia:* Participants will be instructed regarding the signs and symptoms of hyperglycemia and are to call the clinic with any concerns. To minimize the risk of symptomatic hyperglycemia, the following procedures will be followed:

- o If HbA1c $\geq 8\%$ at any routine quarterly visit, therapy will be invigorated by frequent telephone contact and/or visits to encourage optimal medication adherence and lifestyle choices. Participants with diabetes will be asked to perform self monitoring of blood glucose twice a day and whenever they have symptoms of hyperglycemia or feel ill for any reason. They will be asked to report persistent readings above 200 mg/dl to the clinic staff, who will request that the patient check ketones and determine from the presence of symptoms and/or ketones whether the participant needs to be brought to the research clinic for interim assessment. HbA1c will be obtained at the next quarterly visit. If HbA1c remains $\geq 8\%$ but $< 8.5\%$ frequent contact will be maintained.
- o If HbA1c $\geq 8.5\%$ at any routine quarterly visit, therapy will be invigorated (see MOP for details) and HbA1c is repeated after 6 weeks. The daily self care and reporting will be the same as for participants with a HbA1c $\geq 8\%$. If the HbA1c remains $\geq 8.5\%$, outcome assessment will be scheduled in 2 weeks (i.e., regardless of time since randomization).
- o If at any time – either a routine visit or when a participant is brought in due to symptoms – the HbA1c $\geq 9\%$, therapy will be invigorated (see MOP for details), the HbA1c will be repeated within 2 weeks and, if confirmed, the participant will be scheduled for immediate outcome measurement. Once outcome measures are completed, the participant is started on insulin glargine, 0.5 units per kilogram given in the evening and transferred back to their primary care provider for ongoing care.
- o Temporary use of insulin: Some patients may require temporary suspension of study drug and use of insulin for temporary medical conditions such as hospitalization for injury, surgery or other intercurrent illness. Any type or dose of insulin can be used at the discretion of the treatment team. In such cases, an attempt is made to withdraw insulin once the acute event has resolved and study drugs are resumed. If insulin cannot be weaned off within 4 weeks, the patient is censored at that time.
- o Self monitoring of blood glucose: Participants with diabetes will be asked to monitor their fasting blood glucose each morning, and as needed based on clinical status. During temporary insulin therapy, patients are asked to increase their monitoring to twice a day (fasting in the morning and 2 hours after the largest meal). The target for the fasting glucose will be 70-150 mg/dl, and the target for post-meal glucose will be 100-200 mg/dl.
- o Metabolic decompensation is defined as hyperglycemia (plasma glucose > 300 mg/dl) accompanied by significant symptoms (e.g., vomiting, dehydration, lethargy) and/or moderate or large urinary ketones. The participant will be evaluated to determine if temporary use of insulin therapy is required. All patients are educated to contact the study coordinator if they experience metabolic decompensation. This education is reinforced at study visits. Once insulin is started, the site will attempt to wean insulin

- within 4 weeks. If insulin cannot be weaned off within 4 weeks, the patient will be censored at that time.
- o If outcome measurements are performed prior to the scheduled time points of 12 or 15 months, once completed the participant will be referred back to their primary care provider for further care.
- *Gastrointestinal (GI) symptoms* are a common occurrence with metformin. However, these symptoms more commonly occur early in the course of treatment. All eligible participants will be slowly titrated to the maximal tolerated doses of metformin, in order to minimize gastrointestinal side effects. For metformin, the dose will be started at 500 mg daily and titrated slowly to 1000 mg bid. If GI side effects develop and are mild, the patient will be encouraged to remain on the study medication. If GI side effects are moderate or difficult to tolerate, metformin will be reduced to the next lowest dose (for example, 1000 mg bid to 1000 mg + 500 mg; 1000 mg + 500 mg to 500 mg bid; etc.). If symptoms persist, metformin will be reduced to the next step. If GI symptoms resolve, metformin will be re-escalated by 500 mg per day each week until reaching the previously tolerated dose. The participant will continue on the maximum tolerated dose.
 - *Anemia* may be an adverse effect of metformin. It is defined as hemoglobin <10 gm/dl, or a decline in hemoglobin by 2 gm/dl from study entry. If anemia persists for more than six months despite appropriate therapy, consideration will be given to discontinuing study medication.
 - *Renal insufficiency* increases the risk of lactic acidosis associated with metformin. To assess renal insufficiency, serum creatinine and estimated GFR (eGFR) will be calculated using the CKD-Epi equation after six months on therapy. Participants must have an eGFR of 45 mL/minute/1.73 m² or higher to be eligible. Metformin will be discontinued if eGFR is below 30 mL/minute/1.73 m² at the Month 6 visit. If eGFR ≥30 and <45 mL/minute/1.73 m² then the RISE Safety Committee will review the case to assess the benefits and risks of continuing treatment, and make a recommendation to the clinical center investigators about whether to continue the participant on metformin.
 - *Mild hypoglycemia* is common in subjects with prediabetes or diabetes being treated with medications to lower glucose levels into or near the normal range. Participants will be educated to recognize and treat mild hypoglycemic episodes and to contact study staff to report hypoglycemic episodes or receive advice. Adjustments to study medication will be made when appropriate.

- *Severe hypoglycemia* is defined by the need to be treated with glucagon, the need for a third party to resolve a hypoglycemic episode, or loss of consciousness or seizure. Study medications will be adjusted downward as appropriate. Severe hypoglycemia is not expected in the population of youth being studied (obese, insulin resistant youth with prediabetes and type 2 diabetes) with the type and the low dose of insulin being proposed. In support of the safety of glargine, the recent ORIGIN trial studied a similar population (subjects with prediabetes defined as impaired fasting glucose or impaired glucose tolerance and subjects with type 2 diabetes). In ORIGIN, 12,537 subjects with were randomized to receive glargine (with a target fasting blood glucose level of ≤ 95 mg/dL) or standard care [64] for a mean duration of 6.2 years. Hypoglycemia in ORIGIN was minimal despite the very large sample size and long duration of treatment. In the ORIGIN study, there was also less hypoglycemia in subjects with prediabetes than diabetes. Hypoglycemia will also be minimized by frequent blood glucose monitoring during the glargine portion of the study. In addition, the mean BMI in the adult ORIGIN study was 29.85 kg/m^2 , whereas in the pediatric TODAY study the mean BMI was 34.5 kg/m^2 [1]. As a result, we would expect our pediatric patients to be more insulin resistant and less susceptible to hypoglycemia than in adults.
- *Metformin* is temporarily discontinued 24 hours before, during, and for 48 hours after any of the following events to reduce the risk of lactic acidosis: 1) procedure involving the injection of contrast dye; 2) surgery or other procedure requiring general anesthesia; 3) any illness that could be associated with hypoxia, circulatory failure, or dehydration; 4) hospitalization. Serum creatinine will be rechecked no sooner than 48 hours after the conclusion of the event and study medication recommenced if appropriate.
- Other indications for temporary or permanent discontinuation of study medication include:
 - *Pregnancy*: Study medications and protocol visits will be discontinued if a participant becomes pregnant. The participant will be discontinued from the study and referred to a high risk obstetrics clinic for further care. Study medications will not be administered if a participant plans to become pregnant.
 - *Lactation*: No study medication will be administered to women who are nursing a baby.
 - *Lactic acidosis*: Any study participant who experiences a bout of lactic acidosis will have metformin permanently discontinued.
 - *Dermatological problems*: Any study participant who experiences severe dermatological problems, such as urticaria, bullous rashes, exfoliative dermatitis, Stevens-Johnson syndrome, thought to be related to study medication will have study medication permanently discontinued.
- Adverse effects of the study procedures may occur very rarely and include:

- *Glucose injection and infusion:* Irritation of a vein resulting in phlebitis can occur with administration of concentrated glucose solutions. The risk will be decreased by minimizing the use of concentrated solutions, monitoring the veins closely during the infusion and selecting large veins for infusion of solutions.
- *Arginine:* Overdosage, especially in children, can be fatal. To reduce this risk, the dose of arginine will be weight based (0.07 gm/kg) with a maximum dose of 5 gm per dose.

7.5 Potential Benefits

There is potential benefit of participation by individuals with either prediabetes or type 2 diabetes. Prediabetic participants are at increased risk of developing diabetes and may benefit from the frequent monitoring and testing that will allow earlier recognition should their condition progress. The DPP also demonstrated that metformin reduced the risk of progression to diabetes by 31% over three years in adults with prediabetes; metformin has also been shown to lower blood sugar, improve elevated liver enzymes and in girls, improve ovarian dysfunction [59]. Insulin glargine treatment is also predicted to slow progression from prediabetes to type 2 diabetes, potentially by resting the beta cell. Participants with type 2 diabetes will benefit through the close monitoring and the improvement in glucose control that should occur in all subjects. In addition, they have the potential to receive insulin that should further improve glucose control and potentially slow progression of their disease by resting the beta cell. In particular, results of the ORIGIN study showed that not only did glucose control improve in adults with prediabetes and type 2 diabetes while on glargine, but his effect persisted off medication. Participants with prediabetes at the start of the trial (n=1456) were followed-up approximately 3 months after glargine discontinuation. In this group, subjects who received glargine had a 28% reduction in the development of diabetes at the 3 month follow-up after discontinuation of glargine, likely from improved beta cell function. Finally, as all of our proposed subjects have prediabetes or type 2 diabetes, conditions that are becoming more prevalent and carry with them the risk of additional complications, participation will also benefit the individual, the researchers and society through the gaining of new knowledge.

7.6 HIPAA – Protection of Patient Information

All data collected in the process of pre-screening, screening, and conducting the proposed research will be stored and maintained locally and centrally in compliance with HIPAA regulations. Access to study data will be secure with limited, password-protected access. Only study personnel who are IRB approved will have access to data collected as part of these studies. Data entered into the central database will be stored at the CoC on a server that is maintained with the highest stringency of protection. Similarly, data entered into local

databases will be stored at the clinical center on a server that is maintained with the highest stringency of protection.

8 ADVERSE EVENT REPORTING

An adverse event is defined as any medical problem experienced by a RISE participant whether or not considered intervention-related by the clinical center staff. The timely and complete reporting of adverse events is a critical requirement in the conduct of this trial. This trial will be conducted under an IND and will comply with all FDA reporting requirements and those of the pharmaceutical sponsors.

8.1 Definition of Serious Adverse Events

- a. The event results in an inpatient hospitalization (any overnight stay associated with an admission).
- b. The event results in the prolongation of a hospital stay.
- c. The event results in permanent or severe disability.
- d. The event results in death.
- e. A pregnancy results in a congenital anomaly.
- f. The event results from an overdose (either accidental or experimental) of the study medication.
- g. The event is life-threatening.
- h. Treatment is required to prevent a serious event.

8.2 Non-serious Adverse Events

Non-serious adverse events are all AEs which do not meet the above criteria for “serious”.

8.3 Reporting Adverse Events

AEs will be ascertained in an unbiased manner using standard questions that are identical and identically administered to participants in all treatment arms. To accomplish this, AEs will be reported on a standard form that is completed by the study staff at each regular study visit following commencement of study-related activities. Targeted non-serious AEs (e.g., abdominal pain) are ascertained by asking questions relating to specific events of import in prediabetic or diabetic participants as well as side effects that may be associated with any of the study treatment arms. AEs also include any significantly abnormal laboratory result obtained on the patient between visits or at the time of the visit.

In order to facilitate timely reporting of SAEs to the FDA by the NIDDK, the clinical center staff who learn of an SAE must data enter the completed RISE Serious Adverse Event Report prior to

the close of the following business day. Upon request, all SAEs will be reported within the prescribed period to the relevant pharmaceutical sponsors.

8.4 Tracking Adverse Events

- *Serious Adverse Events:* SAEs will be monitored by the RISE Safety Monitoring Committee, which will remain blinded to treatment arm. The external DSMB will monitor SAEs by treatment arm. It is important to note that all serious and unexpected AEs must be reported to the CoC, regardless of the drug-related assessment. For example, a patient struck by lightning requires a report, even though this is not likely to be a drug related event.
- *Non-serious adverse events:* Non-serious AEs are tabulated by the CoC in periodic reports. Summaries of the AEs, tabulated by clinic, are provided to the Safety Monitoring Committee, which reviews this summary during one of its regularly scheduled meetings.
- *Safety Monitoring Committee:* The Safety Monitoring Committee reviews AEs in a blinded fashion. The committee considers whether changes in the protocol (monitoring, consent process, etc.) are indicated based on the occurrence, frequency, or severity of AEs. The committee also evaluates whether there is any clustering of AEs by clinic. Any concerns on the part of the Safety Monitoring Committee may be referred to the Safety Review Officer and/or DSMB, which can review SAEs in an unmasked manner.
- *Safety Review Officer:* The Safety Review Officer will review any SAEs where the Safety Monitoring Committee does not agree about relatedness in an unblinded fashion, and will confirm or reject the causality determination of the SAE to study intervention. As deemed necessary, he/she may contact the local site PI to obtain additional information about the SAE. Any concerns on the part of the Safety Review Officer may be referred to the DSMB.

8.5 Emergency Unmasking

The Safety Monitoring Committee remains blinded to treatment group. If a SAE warrants unblinding, an on-call member of the Safety Monitoring Committee is available for consultation at all times. Unblinding will be performed by a selected member of the study group in combination with the CoC.

9 STATISTICAL CONSIDERATIONS

All analyses will be conducted under the intention-to-treat principle using the treatment as assigned to each participant, and using all available data from all participants. Analyses of study data will be conducted to address the primary and secondary objectives of the trial, other

stated objectives, and other interrelationships among elements of study data of interest to the investigators and of relevance to the objectives of the study.

9.1 Primary Outcome and Analyses

Two primary outcomes each measuring β -cell function after 3-months of washout will be assessed for this trial. Analysis of covariance will be used to compare the two intervention groups after the washout. All analyses will be adjusted for the baseline value of each outcome. Because we are only interested in improvements in β -cell function in youth treated with glargine + metformin vs. metformin alone, analyses will be tested using a one-tailed test at the $\alpha=0.05$ level to detect a benefit of glargine + metformin. The two primary outcomes will be analyzed separately with a total type I error probability of 0.05 for each, one-sided, i.e. without an adjustment for two separate outcomes.

9.2 Secondary Outcomes and Analyses

9.2.1 Measures of β - and α -cell Function and Glucose Tolerance

Comparisons of the primary study outcomes will be made for those with vs. without diabetes at study entry, by race/ethnicity and sex, by baseline HbA1c and β -cell function, and by categorical groups of various biomarkers.

Analysis of covariance will be used to compare the two intervention groups for the primary measures of β -cell function at the end of the active intervention phase (12-months) and 9-months post-washout, as well as for additional continuous variables of interest at both the end of the intervention phase (12-months) and at 3-months and 9-months post-washout. As for the primary outcomes, all analyses will be adjusted for the baseline value of each outcome.

An important secondary analysis of this study is to determine whether β - and α -cell function from OGTT and fasting samples are sufficiently well correlated with more robust assessments of β - and α -cell function obtained from the hyperglycemic clamp to validate their use in large clinical trials. For these analyses, Pearson and non-parametric Spearman correlations of simple versus sophisticated measures of β - and α -cell function will be computed. Correlations will be assessed for measures made both on and off therapy.

Finally, to examine biomarker associations with glucose metabolism, Pearson and non-parametric Spearman correlations of each biomarker with β - and α - cell function, insulin sensitivity and glucose tolerance measures will be determined. In addition, multiple linear regression models will be developed to predict measures of glucose metabolism with the most informative biomarker sets.

9.3 Sample Size/Power Calculations

As this is a proof-of-principle trial, we have chosen 2 measures of β -cell function as co-primary outcomes. They measure different components of β -cell function, and we have no basis of determining whether one or the other is likely to change following the interventions. There is little preliminary data on the expected differences in either of the primary outcomes following a washout. Several unpublished analyses provided ranges of possible differences between treated and placebo patients, as well as expected correlations between baseline and follow up measures. Therefore, sample size was based on a minimum effect size equal to the difference between the two groups divided by the standard deviation (SD) of 0.57 in favor of the glargine + metformin group at a power of 80%. A one-sided significance level of $\alpha=0.05$ to detect a benefit of glargine + metformin was used for each comparison, and a conservative correlation of 0.5 between baseline and follow up measures. A sample size of 39 per arm (78 total) at the end of the washout provides $\geq 80\%$ power to detect a minimum effect size of 0.57 favoring glargine + metformin for either of the primary outcome measurements (see Table 3) using a t-test from a baseline-adjusted analysis of covariance. A higher effect size will result in significantly increased power. A total of 90 participants will be recruited to allow for a 10% loss to follow-up over the course of the study.

Table 3: Power for a sample size of 78 at end of study (39/treatment arm)

Actual Power	Effect Size
90.8%	0.68
87.7%	0.64
84.5%	0.61
81.1%	0.58
77.6%	0.55

9.4 Interim Analysis Plans

The CoC will provide interim analyses of primary and major secondary trial outcomes to the DSMB on a predefined schedule. These results will not be shared with the study group unless the DSMB recommends early stopping of the trial.

9.5 Stopping Rules

The DSMB will monitor trial outcomes as they emerge for futility with specific rules outlined in the DSMB Monitoring Plan. This trial will not be stopped for lack of efficacy, as it is a proof-of-principle study with small numbers of participants in each treatment arm.

9.6 Handling of Missing Data

It is anticipated that a small number of participants will require immediate rescue therapy and be unable to have the 3-month post-washout evaluation. In these cases, the primary outcome will be missing. A sensitivity analysis which includes these participants will use a conservative approach by assuming that these participants have worse function than the participants who were measured. This is implemented by ranking the observed function values from the participants who completed the washout evaluation, and assigning a lower value (or worst rank) to those with missing data [110]. The groups are then compared using a Wilcoxon rank test.

10 DATA PROCESSING AND MANAGEMENT

10.1 Data Management System

Data are entered by the clinical centers using a web data entry application that directly enters study data into the CoC's study database. The web application guides the clinical site staff member through the data entry process. If an invalid response is entered, the website signals and provides a message about the error and how to solve it. At any point during entry, the staff member can make an electronic note concerning a particular response. Valid individual responses are saved as soon as they are entered. The system includes programmed skip patterns as required by the case report forms, and also includes quality control checks such as lists of valid values for multiple choice items. The system provides automated consistency checking so the study staff can resolve inconsistencies quickly without a lengthy communication with the CoC. The same checking is also run on the central database at the CoC to verify that centers are resolving consistency checks.

10.2 Data Transfer

Newly entered clinical center data are received by the CoC immediately upon data entry. The CoC merges newly received data with the accumulated data in a SAS database. Data transfer from central units such as the central laboratory will be through the CoC data management system.

10.3 Quality Control

Range checks, inter-item checks, cross-table checks, and double data entry verification are used where appropriate to ensure accurate data entry. Specific quality control procedures are run to check for missing, incorrect, and questionable values immediately after they are entered. Reports with the necessary patient identifying information and the problem values are printed

and sent to the clinical centers for correction or verification. When returned, corrected values are entered and checked again for consistency with other items. The goals are to make quality control a continuous process, to make the turnaround time between error detection and correction as short as possible, and to document any changes made to the database.

10.4 Back-up, Data Security and Confidentiality

The CoC adheres to the George Washington University Biostatistics Center's data backup and security policies to ensure the safety and confidentiality of the data. Backup procedures include: twice-weekly system backup, daily incremental back-up, and off-site disaster recovery backup. Security procedures include: logon and link password protection, and for internet access, separate Web servers which use SSL and encryption algorithms. Virus and malware protection software is used on all computers and is updated on an hourly basis. All portable computers employ full disk encryption. George Washington University computing facilities provide support in the event of a disaster. Access to the server and databases is secured by use of login user accounts and passwords. Remote access is granted only to authorized users and is accomplished using a secure virtual private network (VPN). Appropriate filtering/firewall setup is used to prevent unauthorized access.

10.5 Tracking Study Progress

The purpose of tracking reports is to keep the collaborative group informed of study progress, and to report special problems and resolutions. Reports will be produced regularly by the CoC, as directed by the Steering Committee. These reports will be distributed to the study group through the study website.

Tracking reports include the following types of information:

- screening and enrollment (versus goal), by clinical center, gender, and race/ethnicity
- tables describing adherence to the study protocol (attendance at scheduled study visits, study intervention compliance)
- database inventory
- number of data edit queries generated and outstanding, by clinical center
- progress of analysis and manuscripts
- Drop-out or loss to follow-up

10.6 Archiving and Study Close-out

At the end of the study, after all data have been received and edited, the database is archived in computer readable format, including documentation files, files of study documents (such as

forms annotated with variable names, protocols, and manuals of procedures), data files in the form of SAS transport files and input statements, data dictionaries, and program code documenting any derived variables. After the study is complete, all data will be available to RISE study investigators and to investigators from outside the study in a manner consistent with the NIDDK's data distribution procedures. Data will be stored at a readily accessible, password-protected website.

11 STUDY ADMINISTRATION

This randomized clinical trial is one of three studies conducted by the RISE Study Consortium. RISE is a collaborative study group funded by the NIDDK of the National Institutes of Health (NIH) under a cooperative agreement mechanism. The goal of the RISE Study is to test different interventions to preserve β -cell function in separate trials, with shared procedures and data collection approaches allowing for the ability to compare data across studies and combine data from individual studies by harmonizing study outcomes and data collection. The RISE Study investigators will be conducting three separate clinical trials. The investigators for each trial are responsible for recruiting participants and implementing their respective protocols. In addition, the RISE Study investigators participate in consortia activities, as described below.

11.1 Organization

The major organizational components and their responsibilities are described:

- The *RISE Steering Committee*, comprised of the principal investigators of the clinical centers, the CoC, and the NIDDK project office, is the primary decision making body for the study with overall responsibility for the design and conduct of the common elements of the study protocols.
- The *NIDDK project office* participates in all decision-making activities and selects and oversees the activities of the DSMB.
- The *Coordinating Center (CoC)* located at the George Washington University Biostatistics Center operates under subcontract to the Seattle Institute for Biomedical and Clinical Research (SIBCR). The CoC has responsibility for coordinating the study, including production and distribution of materials and documents, set-up and administration of the data management system, maintenance of the central database, analysis of primary study results, distribution of final study data to the clinical centers and NIDDK repository, and reporting of results in collaboration with the other investigators.
- The *Central Blood Laboratory (CBL)* operates under subcontract to the Seattle Institute for Biomedical and Clinical Research. The CBL is responsible for providing procedures for the

handling, storage, and shipment of blood specimens, for performing the tests and assays, for performing quality control, for providing patient-level reports to clinical centers, and for transferring results to the CoC.

- The *DSMB* is composed of outside experts in the design and conduct of clinical trials, and in type 2 diabetes. The board is responsible for reviewing the study documents, monitoring study progress, and monitoring patient safety.
- *Working committees* include Outcomes, Recruitment and Retention, Safety and Monitoring, Publications and Presentations, Ancillary Studies, Lab Quality Control, and Program Coordinators. Committees can be discontinued and additional committees can be created as required.

11.2 Central Laboratories and Reading Centers

In collaboration with the CoC and study investigators, central laboratories and reading centers perform the following tasks:

1. Establish procedures and standards for training staff involved in the measurement, collection, preparation, handling, transfer, and all other procedures and processes.
2. Conduct training sessions and contribute training materials to the study manuals of procedures.
3. Provide or facilitate the acquisition of equipment and materials, including specifying brands, sizes, and suppliers as applicable.
4. Establish procedures for data entry and transfer of data to CoC.
5. Develop procedures for the internal as well as external quality control, and provide periodic reports on the quality control surveillance.
6. Provide long-term storage of reserve specimens or materials as directed by the Steering Committee for use in ancillary or future studies.

Each director represents the laboratory or center at RISE Steering Committee meetings, on Steering Committee conference calls, and on other conference calls where the director's participation is deemed necessary.

11.3 Training and Certification

During the start-up period, clinic staff will receive central training and certification at a training workshop held by the study group. The CoC staff and selected clinical center staff with expertise in various study components will provide instruction in all aspects of the study. The purpose of the training workshop is to provide training for study staff in order to insure that the

study is conducted in a standardized manner across all participating centers. The training, based on the study manual of procedures, includes review of study design, focus on eligibility criteria, subject follow-up schedule and assessments, physical, metabolic, processing and shipment of specimens, use of data entry software and electronic forms, transferring data to the CoC, maintaining patient and data confidentiality, and patient treatment guidelines.

Prior to being allowed to recruit participants, each clinical center must pass certification criteria, including satisfactory participation in training as above, supplying the CoC with an IRB approval letter and stamped informed consent forms. Details of certification are provided in the MOP.

Throughout the study, new staff will be trained at the appropriate clinical center and by CoC staff where appropriate. Clinic staff will re-certify annually on identified procedures. Records of certifications and training will be maintained at the clinical sites.

11.4 Site Visits

The Steering Committee will be responsible for ongoing monitoring of the performance of study components.

There are two types of site visits that can be conducted (1) scheduled monitoring and (2) as needed to address specific problems.

The RISE Study does not anticipate scheduled monitoring site visits.

If necessary, site visits will be conducted to address specific problems at a clinical center. Depending on the specific issues, site visits will be attended by the study chair or designee, the NIDDK project office, the CoC, clinical center coordinators, and others as needed. Each visit will follow a predetermined format and site visitors will complete a checklist to record findings. The site visit team will review study procedures and compare data collection records to listings from the central database. A formal site visit report will be provided to the clinical center and to the RISE Executive Committee to aid in correcting any issues found, and a follow-up site visit will be conducted if necessary.

11.5 Study Website

The CoC maintains the study website, which is a secure site requiring a user ID and password combination for access. The web server utilizes the Secure Socket Layer (SSL) protocol that encrypts all traffic to and from the server. Investigators, coordinators, consultants, and other study staff who would benefit from access to the information on the website are each given a

unique user ID and password, which identifies the user to the web server and can be used to restrict access to particular web pages if desired.

The website contains study documents such as the protocol, manual of procedures, and forms, study calendar, directory, meeting and conference call information, links to other sites, tracking reports, minutes, and agendas.

11.6 Conflict of Interest Policy

The RISE Study investigators have adopted a conflict of interest policy similar to that used by other NIDDK collaborative groups. On an annual basis or whenever there is a significant change in status, RISE collaborators are required to disclose any financial or related interest that could present an actual conflict of interest or be perceived to present a conflict of interest. Disclosure is required to protect each individual's reputation and career from potentially embarrassing or harmful allegations of inappropriate behavior, and to protect the integrity of RISE Study research. Conflict of interest forms are kept on file at the CoC, and all conflicts including any newly acquired, are declared at each study group meeting.

The RISE Ethics Committee (NIDDK Project Scientist, NIDDK Program Official and study group member) determine (1) if the disclosed interests could directly and significantly affect the performance of study responsibilities and (2) the actions needed for management, reduction, or elimination of the conflict. In addition to complying with the RISE conflict of interest policies, collaborators must certify to the Ethics Committee that they have complied with all of their local and institutional requirements regarding conflict of interest and disclosure. This is accomplished by supplying the CoC with copies of the local IRB letter of approval and stamped informed consent form(s). Should an institution make a determination regarding an investigator's potential conflict of interest that could affect participation in RISE, the local clinic should report this to the RISE Executive Committee.

11.7 Publications and Presentations Policy

The Publications and Presentations Subcommittee (PPS) will coordinate, monitor, review, and assume responsibility for overseeing the preparation of all study-wide communications (press releases, interviews, presentations (oral and posters), and publications) relating to the scientific aspects of the study. There will be no publication or presentation of study plans or results, including ancillary studies, which have not been reviewed and approved by a majority of the PPS, and for some types of communications, a majority of the Steering Committee. The PPS may also help to identify publication opportunities in areas where productivity is lacking or low.

With respect to publications and presentations from the RISE Study consortium, the goals of the PPS are to:

1. Ensure accurate, uniform, timely, and high quality reporting of RISE activities and results;
2. Preserve the scientific integrity of the study;
3. Safeguard the rights and confidentiality of participants;
4. Assure that the timing of publications and presentations serves the right of the public to know the results of the program without jeopardizing its conduct; and
5. Ensure that appropriate credit is acknowledged for people responsible for RISE and the data being reported and for the funding organizations.

Detailed policies are found in the Manual of Operations.

11.8 Ancillary Studies Policy

The Ancillary Studies Subcommittee will evaluate all proposals for studies that involve RISE participants and/or data that are not a part of the protocol. These studies may be done in all RISE participants or only on a subset of participants in RISE. Ancillary studies may make use of data and/or samples already collected from RISE participants or may involve the collection of new data and/or samples. The RISE Ancillary Studies Subcommittee must review all proposed ancillary studies and these must receive final approval by both the Steering Committee and DSMB. Major factors in consideration of ancillary studies will include:

- Clinical importance and scientific validity;
- Compatibility of goals with those of RISE; and
- Burden on study subjects and staff, including those at the CoC

Approved ancillary studies will be reviewed by the DSMB. Detailed policies are found in the Manual of Operations. Ancillary studies will have to obtain funding from outside the study.

11.9 Protocol Amendments

Adoption of protocol amendments requires two-thirds majority approval by voting members of the RISE Steering Committee and approval by the DSMB. The amended protocol is resubmitted to the IRB, and the participant consent is revised appropriately.

11.10 Repository for Storage and Distribution of RISE Data and Samples

At the end of the study, de-identified research data and samples of blood and urine will be provided to the NIDDK Central Repositories, a research resource supported by the National Institutes of Health. The Repository collects, stores, and distributes biological samples and associated data from people with many kinds of disorders, from unaffected family members, and from other healthy people. The purpose of this collection is to make samples available for use in research for the study of obesity and diabetes and related complications after the RISE Study is completed. Sending samples to the Repository may give scientists valuable research material that can help them to develop new diagnostic tests, new treatments, and new ways to prevent or postpone the onset of obesity and/or diabetes.

As a component of the informed consent process, all participants will be asked to provide specific informed consent for release of data and samples to the NIDDK Repositories. Before the RISE Study investigators send data or samples to the Repository, each sample and data record will be given a code number and the data will be de-identified according to HIPAA requirements. Participants may choose to participate in RISE but not provide consent to have their samples and/or data transferred to the NIDDK Repository.

12 STUDY TIMELINE

The study timeline allows for recruitment over the first 3 years of the study, which commences after all approvals have been obtained (DSMB, FDA, IRBs, CTAs or CRADAs), central study training has been performed and all study medications and supplies have been procured. Intervention and washout phases occur through the middle of year 5 and presentations and publications throughout the period of the study.

13 LITERATURE CITED

1. The TODAY Study Group, A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med*, 2012. 366(24): p. 2247-56.
2. Kahn, S.E., R.L. Hull, and K.M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, 2006. 444(7121): p. 840-846.
3. Dunning, B.E. and J.E. Gerich, The role of α -cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. *Endocr Rev*, 2007. 28(3): p. 253-83.

4. Bacha, F., et al., Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. *Pediatr Diabetes*, 2012.
5. Giannini, C., et al., Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study. *Diabetes*, 2012. 61(3): p. 606-14.
6. Sjaarda, L.A., et al., HbA1c Diagnostic Categories and beta-Cell Function Relative to Insulin Sensitivity in Overweight/Obese Adolescents. *Diabetes Care*, 2012.
7. Michaliszyn, S.F., et al., Metabolomic Profiling of Amino Acids and beta-Cell Function Relative to Insulin Sensitivity in Youth. *J Clin Endocrinol Metab*, 2012. 97(11): p. E2119-24.
8. Sjaarda, L.G., et al., Oral disposition index in obese youth from normal to prediabetes to diabetes: relationship to clamp disposition index. *J Pediatr*, 2012. 161(1): p. 51-7.
9. Burns, S.F., et al., Declining beta-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. *Diabetes Care*, 2011. 34(9): p. 2033-40.
10. Tfayli, H., S. Lee, and S. Arslanian, Declining beta-cell function relative to insulin sensitivity with increasing fasting glucose levels in the nondiabetic range in children. *Diabetes Care*, 2010. 33(9): p. 2024-30.
11. Giannini, C. and S. Caprio, Islet function in obese adolescents. *Diabetes Obes Metab*, 2012. 14 Suppl 3: p. 40-5.
12. Bacha, F., et al., Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. *Pediatr Diabetes*. 13(5): p. 376-83.
13. Kester, L.M., H. Hey, and T.S. Hannon, Using hemoglobin A1c for prediabetes and diabetes diagnosis in adolescents: can adult recommendations be upheld for pediatric use? *J Adolesc Health*. 50(4): p. 321-3.
14. Garvey, W.T., et al., The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. *Diabetes*, 1985. 34: p. 222-234.
15. Ilkova, H., et al., Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. *Diabetes Care*, 1997. 20(9): p. 1353-6.

16. Weng, J., et al., Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. *Lancet*, 2008. 371(9626): p. 1753-60.
17. The Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*, 2002. 346: p. 393-403.
18. Kahn, S.E., et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med*, 2006. 355: p. 2427-2443.
19. Kahn, S.E., et al., Effects of rosiglitazone, glyburide and metformin on β -cell function and insulin sensitivity in ADOPT. *Diabetes*, 2011. 60: p. 1552-1560.
20. Fehse, F., et al., Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metab*, 2005. 90: p. 5991-5997.
21. Drucker, D.J. and M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet*, 2006. 368: p. 1696-1705.
22. Nadeau, K.J., et al., Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. *J Clin Endocrinol Metab*, 2009. 94(10): p. 3687-95.
23. Dabelea, D., et al., Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study. *Diabetologia*. 54(1): p. 78-86.
24. Hannon, T.S., et al., Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. *Int J Pediatr Obes*. 6(2): p. 157-60.
25. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. 2011 [cited 2011 2/13/2011]; Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
26. The SEARCH for Diabetes in Youth Study Group, Incidence of diabetes in youth in the United States. *JAMA*, 2007. 297(24): p. 2716-24.
27. Li, C., et al., Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006. *Diabetes Care*, 2009. 32(2): p. 342-7.

28. American Diabetes Association, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 1997. 20: p. 1183-1197.
29. International Expert Committee, International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*, 2009. 32(7): p. 1327-34.
30. Tuomilehto, J., et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*, 2001. 344: p. 1343-1350.
31. The DREAM Trial Investigators, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet*, 2006. 368(9541): p. 1096-1105.
32. Ramachandran, A., et al., The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia*, 2006. 49: p. 289-297.
33. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*, 1998. 352: p. 837-853.
34. Jensen, C.C., et al., β -cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. *Diabetes*, 2002. 51: p. 2170-2178.
35. The Diabetes Prevention Program Research Group, Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. *Diabetes*, 2005. 54: p. 2404-2414.
36. Kahn, S.E., et al., The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. *Diabetologia*, 2009. 52: p. 1003-1012.
37. Saad, R., N. Gungor, and S. Arslanian, Progression from normal glucose tolerance to type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates. *Pediatr Diabetes*, 2005. 6(2): p. 95-9.
38. Bacha, F., et al., Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. *Pediatr Diabetes*, 2012.
39. Weyer, C., et al., The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest*, 1999. 104: p. 787-794.

40. Utzschneider, K.M., et al., Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. *Diabetes Care*, 2009. 32: p. 335-341.
41. Poitout, V. and R.P. Robertson, Glucolipotoxicity: fuel excess and β -cell dysfunction. *Endocr Rev*, 2008. 29: p. 351-366.
42. Kloppel, G., et al., Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. *Surv Synth Pathol Res*, 1985. 4: p. 110-125.
43. Butler, A.E., et al., β -cell deficit and increased β -cell apoptosis in humans with type 2 diabetes. *Diabetes*, 2003. 52: p. 102-110.
44. Rahier, J., et al., Pancreatic β -cell mass in European subjects with type 2 diabetes. *Diabetes Obes Metab*, 2008. 10 (Suppl 4): p. 32-42.
45. Hull, R.L., et al., Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. *J Clin Endocrinol Metab*, 2004. 89: p. 3629-3643.
46. Unger, R.H., et al., Studies of pancreatic alpha cell function in normal and diabetic subjects. *J Clin Invest*, 1970. 49: p. 837-848.
47. Muller, W.A., et al., Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. *N Engl J Med*, 1970. 283: p. 109-115.
48. Ward, W.K., et al., Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *J Clin Invest*, 1984. 74: p. 1318-1328.
49. Mitrakou, A., et al., Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. *N Engl J Med*, 1992. 326: p. 22-29.
50. Larsson, H., G. Berglund, and B. Ahren, Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. *J Clin Endocrinol Metab*, 1995. 80: p. 1778-1782.
51. Kirk, R.D., et al., Abnormal pancreatic alpha-cell function in first-degree relatives of known diabetics. *J Clin Endocrinol Metab*, 1975. 40(5): p. 913-6.
52. Tasali, E., B. Mokhlesi, and E. Van Cauter, Obstructive sleep apnea and type 2 diabetes: interacting epidemics. *Chest*, 2008. 133(2): p. 496-506.

53. Seicean, S., et al., Sleep-disordered breathing and impaired glucose metabolism in normal-weight and overweight/obese individuals: the Sleep Heart Health Study. *Diabetes Care*, 2008. 31(5): p. 1001-6.
54. Waters, K.A., et al., Structural equation modeling of sleep apnea, inflammation, and metabolic dysfunction in children. *J Sleep Res*, 2007. 16(4): p. 388-95.
55. Hannon, T.S., et al., Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. *Int J Pediatr Obes*, 2011. 6(2): p. 157-60.
56. Resnick, H.E., et al., Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. *Diabetes Care*, 2003. 26(3): p. 702-9.
57. Foster, G.D., et al., Obstructive sleep apnea among obese patients with type 2 diabetes. *Diabetes Care*, 2009. 32(6): p. 1017-9.
58. Aronsohn, R.S., et al., Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. *Am J Respir Crit Care Med*, 2010. 181(5): p. 507-13.
59. The Diabetes Prevention Program Research Group, Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. *Diabetes*, 2005. 54: p. 1150-1156.
60. DeFronzo, R.A., et al., Pioglitazone for diabetes prevention in impaired glucose tolerance. *N Engl J Med*, 2011. 364: p. 1104-15.
61. Buchanan, T.A., et al., Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes*, 2002. 51(9): p. 2796-803.
62. Chiasson, J.L., et al., Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet*, 2002. 359(9323): p. 2072-2077.
63. The NAVIGATOR Study Group, Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med*, 2010. 362: p. 1463-1476.
64. The ORIGIN Trial Investigators, Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*, 2012. 367(4): p. 319-328.
65. Zinman, B., et al., Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. *Lancet*, 2010. 376: p. 103-111.

66. Lindstrom, J., et al., Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. *Lancet*, 2006. 368: p. 1673-1679.
67. DREAM On Investigators, Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. *Diabetologia*, 2011. 54(3): p. 487-95.
68. The DREAM Trial Investigators, Incidence of diabetes following ramipril or rosiglitazone withdrawal. *Diabetes Care*, 2011. 34(6): p. 1265-9.
69. Garnett, S.P., et al., Researching Effective Strategies to Improve Insulin Sensitivity in Children and Teenagers - RESIST. A randomised control trial investigating the effects of two different diets on insulin sensitivity in young people with insulin resistance and/or pre-diabetes. *BMC Public Health*, 2010. 10: p. 575.
70. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*, 1998. 352: p. 854-865.
71. UK Prospective Diabetes Study (UKPDS) Group, U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. *Diabetes*, 1995. 44: p. 1249-1258.
72. Neumann, A., et al., Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. *Diabetologia*, 2012. 55(7): p. 1953-62.
73. Azoulay, L., et al., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. *BMJ*, 2012. 344: p. e3645.
74. Farilla, L., et al., Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology*, 2003. 144(12): p. 5149-5158.
75. Xu, G., et al., Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. *Diabetes*, 1999. 48: p. 2270-2276.
76. Bunck, M.C., et al., One-year treatment with exenatide improves β -cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. *Diabetes Care*, 2009. 32: p. 762-768.

77. Bunck, M.C., et al., Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on β -cell disposition index in metformin treated patients with type 2 diabetes patients. *Diabetes*, 2010. 59 (Suppl 1): p. A198.
78. Bacha, F., et al., From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. *Diabetes Care*. 33(10): p. 2225-31.
79. Bailey, C.J. and R.C. Turner, Metformin. *N Engl J Med*, 1996. 334(9): p. 574-9.
80. Hemmingsen, B., et al., Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. *BMJ*, 2012. 344: p. e1771.
81. Love-Osborne, K., J. Sheeder, and P. Zeitler, Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. *J Pediatr*, 2008. 152(6): p. 817-22.
82. Triplitt, C., et al., Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. *Diabetes Care*, 2006. 29(11): p. 2371-7.
83. Currie, C.J., C.D. Poole, and E.A. Gale, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia*, 2009. 52(9): p. 1766-77.
84. Mitrakou, A., et al., Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. *J Clin Endocrinol Metab*, 1992. 75(2): p. 379-82.
85. Brunzell, J.D., et al., Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. *J Clin Endocrinol Metab*, 1976. 42: p. 222-229.
86. Kanat, M., et al., Distinct β -cell defects in impaired fasting glucose and impaired glucose tolerance. *Diabetes*, 2012. 61(2): p. 447-53.
87. Vilsboll, T., et al., Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. *Diabet Med*, 2008. 25(2): p. 152-6.
88. Johnston, C., et al., Islet function and insulin sensitivity in the non-diabetic offspring of conjugal type 2 diabetic patients. *Diabet Med*, 1990. 7(2): p. 119-125.

89. Kahn, S.E., et al., Quantification of the relationship between insulin sensitivity and β -cell function in human subjects. Evidence for a hyperbolic function. *Diabetes*, 1993. 42: p. 1663-1672.
90. Ahren, B., Glucagon secretion in relation to insulin sensitivity in healthy subjects. *Diabetologia*, 2006. 49(1): p. 117-22.
91. Larsson, H. and B. Ahren, Islet dysfunction in obese women with impaired glucose tolerance. *Metabolism*, 1996. 45: p. 502-509.
92. Burns, S.F., et al., Declining β -cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. *Diabetes Care*, 2011. 34(9): p. 2033-40.
93. Schwartz, B., et al., Measurement of insulin sensitivity in children: comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. *Diabetes Care*, 2008. 31(4): p. 783-8.
94. Mari, A., et al., Meal and oral glucose tests for assessment of β -cell function: modeling analysis in normal subjects. *Am J Physiol Endocrinol Metab*, 2002. 283: p. E1159-E1166.
95. Cobelli, C., et al., Assessment of β -cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. *Am J Physiol Endocrinol Metab*, 2007. 293: p. E1-E15.
96. Van Cauter, E., et al., Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. *Diabetes*, 1992. 41(3): p. 368-77.
97. Utzschneider, K.M., et al., Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. *Diabetologia*, 2007. 50: p. 2516-2525.
98. Sjaarda, L.G., et al., Oral disposition index in obese youth from normal to prediabetes to diabetes: relationship to clamp disposition index. *J Pediatr*. 161(1): p. 51-7.
99. Lyons, T.J. and A. Basu, Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. *Transl Res*, 2012. 159(4): p. 303-12.
100. Mather, K.J., et al., Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. *Diabetes*, 2008. 57(4): p. 980-6.

101. De Leo, V., et al., Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. *Drugs Today (Barc)*, 2009. 45(10): p. 763-75.
102. Salomaa, V., et al., Thirty-one novel biomarkers as predictors for clinically incident diabetes. *PLoS ONE*, 2010. 5(4): p. e10100.
103. Kolberg, J.A., et al., Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. *Diabetes Care*, 2009. 32(7): p. 1207-12.
104. Akirav, E.M., et al., Detection of beta cell death in diabetes using differentially methylated circulating DNA. *Proc Natl Acad Sci U S A*, 2011. 108(47): p. 19018-23.
105. Karnik, S.K., et al., Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. *Science*, 2007. 318(5851): p. 806-9.
106. Park, S., et al., Serum prolactin concentrations determine whether they improve or impair beta-cell function and insulin sensitivity in diabetic rats. *Diabetes Metab Res Rev*, 2011. 27(6): p. 564-74.
107. Marina, A.L., et al., Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell function. *Diabetes Care*, 2012. 35(3): p. 1119-25.
108. Ota, A. and Y. Wang, Cdc37/Hsp90 protein-mediated regulation of IRE1alpha protein activity in endoplasmic reticulum stress response and insulin synthesis in INS-1 cells. *J Biol Chem*, 2012. 287(9): p. 6266-74.
109. Bang, H., et al., Development and validation of a patient self-assessment score for diabetes risk. *Ann Intern Med*, 2009. 151(11): p. 775-83.
110. Lachin, J.M., Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials. *Controlled Clinical Trials*, 1999. 20(5): p. 408-422.